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ABSTRACT

Kelley, Kevin Daniel. Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2010. Understanding the Molecular Dynamics of YPEL3 and FHIT
Gene Expression.

A comprehensive understanding of the molecular signaling pathways that
regulate cell growth and proliferation is essential in the realization of new
therapeutic options to facilitate early detection and eradication of malignancy.
Understanding the transcriptional regulation of the YPEL3 and FHIT genes forms
the basis of this dissertation. YPEL3, or Yippee-like 3, is a newly identified p53
target gene that inhibits tumor cell growth and is thus itself, a novel tumor
suppressor gene. FHIT, or Fragile histidine triad, is a well known tumor suppressor
gene and is regulated at the transcriptional level by another growth inhibitory
protein, FOXO3a, a Forkhead box transcription factor.
Our laboratory has determined that YPEL3 is a direct transcriptional target of
the tumor suppressor gene p53. The first section of this dissertation provides
significant experimental evidence to validate this observation. Briefly, YPEL3 was
shown to be upregulated downstream of p53 protein stabilization in a microarray
screen that explored global gene expression modulation after RNAi-mediated
reduction of p53’s negative regulators, Hdm2 and HdmX. Genotoxic stress induced
iv

by treatment with DNA-damaging agents resulted in stabilization of p53 protein
along with elevation of YPEL3 transcript and protein levels. Moreover, there exists
a cis-acting p53 response element within the YPEL3 promoter that is bound by p53
in response to this stress. YPEL3 also elicits growth inhibition and decreases in
colony formation when expressed in tumor cells. It is apparent that cells which
express exogenous YPEL3 are forced into a permanent cell cycle arrest, termed
“premature senescence.” Similar growth suppressive phenotypes are typical of
many other known p53 target genes. However, most of these genes are associated
with the regulation of transient inhibition of cell division or the induction of
apoptosis. YPEL3 is unique in its ability to trigger premature cellular senescence.
Indeed, YPEL3 stands out among many other p53 targets because it is among the
first to play a role in this process.
To further understand the mechanism of YPEL3-induced senescence, the
second portion of this dissertation focuses on the generation of a three-dimensional
model of YPEL3’s protein structure. It was hypothesized that predicting YPEL3’s
protein structure may also aid in understanding the molecular events involved in the
induction and maintenance of premature senescence.

Identifying structural

homology between a predicted model of YPEL3 and other known structures may
provide new insights into this process.

This would especially be the case if

homology existed between the predicted structure of YPEL3 and other proteins that
have established functions in stress-responsive or senescence-associated molecular
pathways. By using two independent structural prediction algorithms (Rosetta ab
initio and I-TASSER), I have been able to estimate a three-dimensional model of
v

the YPEL3 protein which has significant structural homology to a family of
Methionine oxidoreductases. These enzymes catalyze redox-mediated antioxidant
reactions which dissipate intracellular reactive oxygen species (ROS) through the
repair of proteins damaged by ROX-mediated methionine to methionine sulfoxide
oxidation. It is even plausible that YPEL3 could be involved in the mediation of
cellular senescence in response to severe oxidative stress. If this is the case, the
implications of this speculation, linking the oxidative stress response to YPEL3dependent cellular senescence, are indeed profound. YPEL3 may not only play a
role in the molecular biology of cancer but also may be involved in the cellular
oxidative stress response as it relates to senescence and aging.
In the third part of this dissertation, FHIT, a tumor suppressor gene often
deleted in epithelial-derived tumors, was also initially postulated to be regulated by
p53 (just as in the case of YPEL3). However, FHIT gene expression was instead
found to be modulated by FOXO3a.

This gene’s expression was induced

coincidentally under similar conditions as p53 such as cell cycle arrest. FHIT is
suppressed by the AKT/PI3K pathway upon growth factor-dependent stimulation.
These protooncogenic kinases phosphorylate and, thereby prevent FOXO3a from
entering the nucleus and activating FHIT gene expression. Thus, FOXO3a is only
able to enter the nucleus in the absence of mitogenic stimulation. FHIT transcript
levels are elevated in response to the removal of mitogen-containing serum from
breast, colon carcinoma, and immortalized mammary epithelial cells. Induction of
FHIT gene expression is dependent on decreased PI3K kinase activity and
subsequent reduced AKT phosphorylation which occur in the absence of growth
vi

factor stimulation. As such, quiescence-dependent elevation of FHIT mRNA can
be elicited independently of mitogen removal, by treatment with PI3K inhibitors, or
attenuated by ectopic expression of constitutively active AKT during serum
deprivation. Furthermore, ectopic expression of FOXO transcription factors result
in the upregulation of FHIT mRNA and protein levels. Additionally, nuclear
shuttling experiments with a FOXO3a-estrogen receptor fusion protein have
demonstrated that FOXO must enter the nucleus to modulate expression of FHIT.
Finally, experiments using shRNA targeting FOXO3a have revealed that the
modulation of FHIT gene expression, downstream of PI3K inactivation, is
dependent on endogenous FOXO3a.
In summary, this project began with investigating the regulation of two
genes derived from a microarray screen to search for new p53 targets. Validation of
YPEL3 as a novel p53 target gene was very straightforward. All assays employed
in characterizing YPEL3 revealed that it behaved exactly as a classic p53
transcriptional target. The latter of the two genes, FHIT, however was determined
not to be a p53 target but rather a transcriptional target of FOXO3a—another tumor
suppressive transcription factor. It is the hope of the author that this information
will serve to enhance our basic understanding of the paradoxically both,
overwhelmingly complex and elegantly simple molecular dynamics of gene
regulation, as it pertains to the biology of cancer.
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PART I
YPEL3: a new p53 target gene that can induce cellular
senescence in tumor cells.

INTRODUCTION TO PART 1
The p53 tumor Suppressor Gene
p53 is a tumor suppressor gene that encodes a transcription factor as its protein
product. Transcriptional target genes of p53 regulate an exhaustive list of cellular
signaling pathways and metabolic processes vital to maintaining cellular and organismal
homeostasis and survival. These include control of cell division, apoptosis, senescence,
DNA repair, angiogenesis, glycolysis, autophagy, and mitochondrial respiration
(Vousden,K.H. and Prives,C. 2009).
Regulation of p53 function by Mdm2 and MdmX
p53 is primarily controlled at the post-translational level, by two negative
regulators: Murine Double Mutant 2 (Mdm2) and Murine Double Mutant 4 or MdmX 1
(Clegg,H.V., Itahana,K., et al. 2008, Danovi,D., Meulmeester,E., et al. 2004, Hu,B.,
Gilkes,D.M., et al. 2007, Klein,C. and Vassilev,L.T. 2004, Meulmeester,E. and
Jochemsen,A.G. 2008, Toledo,F. and Wahl,G.M. 2006, Toledo,F. and Wahl,G.M. 2007).
Both of these proteins can bind to the p53 protein and block its ability to interact with
target gene promoters and regulate their expression (Kruse,J.P. and Gu,W. 2009,

1

The "M" in the acronyms, Mdm2 and MdmX refers to "murine" and can be replaced with "H" to denote the
human homologues, Hdm2 and HdmX, respectively.
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Vousden,K.H. and Prives,C. 2009). Mdm2 is an E3 ubiquitin ligase. As such, it can
attach ubiquitin moieties to p53 protein and target it to the 26S proteosome for
degradation (Clegg,H.V., Itahana,K., et al. 2008). In an unstressed cell, p53 protein levels
and transactivity are kept low and inactive, respectively as a result of the constitutive
proteosomic turnover afforded by Mdm2 (Kruse,J.P. and Gu,W. 2009). If the cell is
exposed to a genomic insult such as a DNA-damaging agent in the form of ultraviolet
light, environmental carcinogen, chemotherapeutic drug or ionizing radiation, the p53
protein will be stabilized (Kruse,J.P. and Gu,W. 2009). Elevation of intracellular p53
protein concentrations and subsequent transactivation of downstream target genes occur
as a result of signaling by upstream DNA damage sensing complexes 2 which activate
PIP3-type kinases ATM and ATR 3. These kinases, once activated can lead to the
inhibition of Mdm2/X-mediated attenuation of p53 function through modulation of Chk1
and Chk2 phosphorylation (Bartek,J., Bartkova,J., et al. 2007, Jazayeri,A., Falck,J., et al.
2006, Roos,W.P. and Kaina,B. 2006). The Chk protein kinase family is able to in turn
phosphorylate Mdm2, MdmX and p53 (Chen,Y. and Poon,R.Y. 2008, Bartek,J.,
Bartkova,J., et al. 2007). This allows p53 to be released from the inhibitory effects
imposed by Mdm2 and MdmX and facilitates the transcriptional regulation of its
downstream target genes.
To further refine this process, post-translational modifications of p53 play key roles
in determining which types of target gene promoters are activated and to what degree. As
an example, whether p53 transactivates pro-apoptotic genes versus cell cycle arrest and
2

Damage sensing complexes include the RAD911 complex as well as single stranded DNA binding proteins such as replication
protein A (RPA) that will bind at stalled replication forks associated with damaged regions of pre-replicated DNA ( Pandita,T.K.,et al 2006).

3

Ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) are serine / threonine protein
kinases belonging to the class IV PI 3-kinase family. They function in the detection of DNA damage as a result of genotoxic events and facilitated the
activation of downstream kinases such as chk2 and chk1 in order to trigger checkpoint dependent- cell cycle arrest or apoptosis (Jazayeri,A. 2006,
Chen,Y. 2008).

2

repair targets is determined in part by phosphorlyation of different key serine residues
including S46 located in the N-terminal transactivation domain of p53 (Vousden,K.H. and
Prives,C. 2009)
In addition to DNA damage, p53 is also activated by perturbations in oncogene
activity. Surprisingly, p53’s ability to detect oncogene overexpression is thought
currently to be even more important to its tumor suppressive function than its activation
downstream of DNA damage-induced cellular stress. In support of this, many recent
independent studies have been conducted which have shown the initial activation of p53
by genotoxic stressors to not be as imperative as was previously assumed for the
prevention of cancer (Vousden,K.H. and Prives,C. 2009).
Once active, p53 will begin to drive the transcriptional expression of a myriad of
transcriptional target genes. 4 Extensively studied downstream effector genes include
those that regulate cell cycle arrest such as p21—a cyclin dependent kinase inhibitor that
inhibits cell division by blocking cyclin D1/D2/E CDK2/4 complexes from
phosphorylating retinoblastoma (Rb) protein. This prevents Rb, another key tumor
suppressor gene important in cell cycle regulation, from releasing pro-proliferative E2F
transcription factors from transcription inhibition (Abbas,T. and Dutta,A. 2009,
Gartel,A.L. 2007). Without this transcriptional repression, E2F-1 becomes an “oncogene
by proxy 5” through loss of Rb, and as such, would become constitutively activated to
induce the transcription of genes important for stimulating cell division— leading to
tumor formation. p53 also increases the expression of genes involved in DNA repair

4

5

p53 can act as both an activator and repressor of transcription.

,

Chen C, Wells AD. Comparative analysis of E2F family member oncogenic activity.., PLoS One. 2007 Sep 19;2(9):e912

3

such as GADD45a (el-Deiry,W.S. 1998). If the cell is not able to repair this damage, it is
currently thought that there are two alternatives. Genes that regulate apoptosis may be
upregulated by p53 as a result of a post-translationally-mediated switch in p53 binding
affinity for apoptotic gene promoters such as BAX, PUMA and APAF- 1 6 This will elicit
a programmed cell death response to eliminate any tumorigenic threat posed by this precancerous cell (el-Deiry,W.S. 1998) Another alternative, rather than apoptosis is that the
cell may enter an irreversible form of cell cycle arrest termed premature senescence.
p53-dependent senescence is activated by many of the same mechanisms that trigger
transient cell cycle arrests or apoptosis, such as pathologic oncogene activation, DNA
damage or telomere dysfunction (Vousden,K.H. and Prives,C. 2009). It was originally
assumed from earlier studies, that after cellular senescence was triggered in a
premalignant cell, the permanent retention of this senescent, but still precancerous cell
occurred in vivo based on in vitro observations. The risk of neoplastic progression was
thought never to be completely eliminated in this case because of the preservation of
these diseased cells rather than apoptotic elimination. It was recently discovered,
however, that senescent cells do not remain stable in vivo as they do in cell culture.
Rather, these cells apparently secrete inflammatory cytokines that result in their clearance
by the innate immune system (Xue,W., Zender,L., et al. 2007).
Target genes regulated by p53 intercede in the pathogenesis of cancer.
One of p53’s most important functions 7 is as a tumor suppressor—preventing

6

BAX PUMA and APAF-1 (Apoptotic peptidase activating factor 1) are transcriptional target genes of p53 that commit the cell
to apoptosis by regulating caspase cleavage, apoptosome formation and mitochondrial permeability of cytochrome C (el-Deiry,W.S. 1998, Roos,W.P.
2006).

7

The p53 protein's involvement in cancer is by far the most well studied aspects of p53, however evolutionarily speaking, the initial biological function
of p53 may have actually been in embryonic development. (personal communication: Arnold Levine, keynote speaker, 2008 International p53 Conference.
Shanghai, China.)
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genomic mutations from becoming permanently integrated into the genome by activating
DNA repair pathways. As previously alluded, even in the event that stable mutations
accumulate, resulting in aberrant oncogene activation or loss of heterozygosity of a tumor
suppressor gene, a second line of defense exists against oncogenesis. This innate
protection orchestrated by p53 leads to the expression of target gene effectors involved in
mediating either transient inhibition of cell division with DNA repair, apoptosis or
senescence. Expression of genes that regulate these processes is maintained in a balanced
equilibrium by p53 to above all, maintain genomic integrity. Thus, if irreparable genetic
damage exists, this equilibrium will shift from expression of genes responsible for
transient arrest and DNA repair and the cell will be forced to take more drastic measures
to avoid incorporation of genetic aberrations. Apoptotic or senescent induction occurs in
this case to remove any further threat of the host cell losing its ability to “self-regulate”
its own replication, and thus prevent carcinogenesis from occurring (Kruse,J.P. and
Gu,W. 2009, Meulmeester,E. and Jochemsen,A.G. 2008, Riley,T., Sontag,E., et al. 2008,
Vousden,K.H. and Prives,C. 2009).
So what if p53 or one of its many transducers or effectors is not functioning
properly or is completely absent? If the faulty or missing gene is at the lower end of the
p53 signaling transduction spectrum such as at the level of target gene or effector, genetic
redundancy typically observed at this level of regulation usually ensures that cellular
homeostasis is still adequately maintained. However, if the malfunction is at a higher
level of regulation or even within p53 itself incurring a disruptive mutation, future
genetic aberrancies that eventually accrue may go unnoticed by these faulty p53surveillance pathways. In this case, DNA damage and subsequent mutations will not be
5

accounted for and repaired but permitted to accumulate. Additionally, the cell will be at
further risk of undergoing oncogenesis if it is unable to respond to anomalous oncogene
activation (i.e. Oncogenic RAS) via p53-mediated premature senescence pathways.
Following the logic of P.C. Nowell’s clonal tumor cell evolution hypothesis
(Nowell,P.C. 1976), mutant phenotypes derived from chance genetic mutations that are,
in themselves advantageous to the cell by perpetuating cellular growth and deregulated
proliferation, are placed under positive selection. Certainly, advantageous mutations
characteristic of a cancerous cell would include those that contribute to oncogene
overexpression or tumor suppressor loss and as a consequence, loss of control over the
cell cycle and eventual tumor formation (see illustration in Figure 20) (Kemp,C.J. 2005,
O'Neil,N. and Rose,A. 2006, Pfeifer,G.P. and Besaratinia,A. 2009, Sidransky,D.,
Mikkelsen,T., et al. 1992).
Indeed, because p53 is such a pivotal component in the cells molecular arsenal
against the development of cancer, functional loss of this gene cannot be tolerated. Many
malignant tumors contain loss or gain of function mutations in both p53 alleles (~50% of
human tumors) which contribute to tumorigenesis. Other cancers have faulty regulatory
or effector pathways up or downstream of p53, respectively, that impede p53’s ability to
perform its tumor suppressive function (Rayburn,E.R., Ezell,S.J., et al. 2009, SanchezBeato,M., Sanchez-Aguilera,A., et al. 2003). Therefore screening for new transcriptional
target genes regulated by p53 is justified to further understand how p53 prevents the
occurrence of cancer.

6

Introduction to Yippee-like 3

Yippee-like 3 (YPEL3) belongs to a five member family of closely related
paralogues—YPEL1-5 that are named in reference to their orthologue—Drosophila
Yippee (Hosono,K., Sasaki,T., et al. 2004a). The Drosophila protein was first identified
in a yeast two hybrid screen for gene products that interacted with Hemolin protein from
Hyalophora cecropia (silk moth) (Roxstrom-Lindquist,K. and Faye,I. 2001). Drosophila
Yippee is suspected to contain a putative metal binding site composed of four cysteines
which could coordinate a metal ion such as zinc and form a zinc finger motif. Yippee
was also found to have 76% amino acid identity with a human cDNA clone which was
later identified as hYPEL5. Additionally, both of these proteins are identical with respect
to two pairs of cysteines suspected to form the zinc finger (Roxstrom-Lindquist,K. and
Faye,I. 2001). In addition, molecular phylogenetic analysis of all five members of the
human Yippee family has revealed a high degree of conservation throughout eukaryotic
evolution. Homology extends across a broad spectrum of orthologous and paralogous
Metazoan amino acid sequences. For example, significant homology can even be
identified when comparing loci from mammalian lineages to those of Mycetazoa (slime
molds) (Baldauf,S.L. and Doolittle,W.F. 1997)(Roxstrom-Lindquist,K. and Faye,I. 2001).
This is an indication that the Yippee gene family may be involved in molecular and
cellular functions that are vitally important to the survival and fundamental physiological
regulation of the eukaryotic cell (Roxstrom-Lindquist,K. and Faye,I. 2001).
Clues toward understanding YPEL3’s biological function
In 2003, a manuscript (Baker,S.J. 2003) detailing YPEL3’s biological
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function in mice was published. This was the first and only report (until 2010) that has
detailed the biological function of this gene’s protein product. It was demonstrated here
that YPEL3 expression was upregulated in differentiating murine myeloid precursor
(MMP) cells as they progressed toward apoptosis; it was also observed that ectopic
expression of YPEL3 was associated with the induction of cell growth inhibition and
apoptosis in these same cells (Baker,S.J. 2003).
Briefly, while searching for genes that might be involved in terminal
differentiation and apoptosis of MMP cells using microarray technology—mYPEL3
(referred to in the manuscript as Small Unstable Apoptotic Protein or SUAP) gene
expression was observed to increase in terminally differentiating MMP cells. Removal of
the cytokine Interleukin-3 (IL-3) from the growth media of these cells normally results in
their differentiation into mature granulocytes followed by eventual programmed cell
death of differentiated granulocytes. Endogenous mYPEL3 was shown to increase in
expression after removal of IL-3 and its upregulation temporally paralleled the entry of
these terminally differentiated granulocytes into apoptosis. It was later shown that when
exogenous SUAP was introduced into this cell line using an IPTG-inducible retroviral
system, a decrease in the ability of stable transductants to form colonies was apparent.
Flow cytometric analysis of the SUAP-expressing cells was employed to demonstrate
that the percentage of actively dividing cells in the mYPEL3-expressing pool was the
same when compared to control cells, thus ruling out cell cycle arrest as a possible
mechanism of growth suppression seen in earlier colony formation experiments.
However, the presence of phosphatidylserine on the outer cell surface—an early marker
for apoptosis, was shown by fluorescently -tagged Annexin V binding to be increased in
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ectopic mYPEL3-expressing MMP cells (Baker,S.J. 2003).
It should also be mentioned, that at the time of this study the human YPEL3 gene had
not been characterized yet nor had it been named. With the fact that it was a relatively
small (14kDa) and unstable 8 protein, found to be linked to the programmed cell death
pathway, it was aptly named: Small Unstable Apoptotic Protein or SUAP 9 in this
manuscript (Baker, 2003).
In a later study, that actually characterized all five human YPEL3 family members,
indirect immunoflorescence using pantropic polyclonal antibodies revealed that the
human Yippee family of proteins may localize to the nucleus, mitotic spindle apparatus
and centrioles (Hosono,K., Sasaki,T., et al. 2004a). However, because expression levels
between YPEL1-4 could differ dramatically from each other and the antibody used in this
study was pantropic—being raised against a peptide sequence occurring in all family
members, this observation should be applied to each paralogue with caution as
overrepresentation of one may mask others’ localization or lack of detection.
Nonetheless, these localization studies are valuable and may indicate that the Yippee-like
gene products could be involved in cell cycle regulation, particularly at the mitotic phase
of the cell cycle (Hosono,K., Sasaki,T., et al. 2004a). Additionally, based on these
observations it has been proposed that YPELs may be involved in other biological
processes occurring in the nucleus such as DNA replication, transcription or chromatin
remodeling—any of which could have significant impact on the regulation of cell growth
and division (Hosono,K., Sasaki,T., et al. 2004b). These data further supported the initial
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In this manuscript it was also reported that YPEL3 protein was very unstable and incredibly difficult to
detect via Western blot.
9
Although the Yippee-like 3 gene actually currently holds two aliases (YPEL3 and SUAP), it will only be
referred to as YPEL3 in this document for simplicity.
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hypothesis that YPEL3 could be involved in regulation of cell growth and proliferation.
Other Yippee family members such as YPEL1 have been shown to be involved in
embryological development. For example, YPEL1 located on chromosome 22q11.2 has
been linked to DiGeorge Syndrome, a disease that is characterized by craniofacial
patterning defects, cardiac abnormalities and thymic hypoplasia and genetic aberrations
involving chromosome 22 (Farlie,P., Reid,C., et al. 2001, Shprintzen,R.J. 2008). Further
support for a role in development stems from the observation that YPEL1 expression is
highly expressed on the ventral side of the embryo, including the branchial arches
involved in craniofacial patterning and development (Farlie,P., Reid,C., et al. 2001). In
addition, it was observed by this same group that ectopic YPEL1 expression in fibroblasts
caused them to transition from the spindle-shaped mesynchemal morphology typical of
these cells, to a more flattened epithelioid shape indicating a possible role in cellular
differentiation (Farlie,P., Reid,C., et al. 2001).
Rationale
A thorough examination of the anti-tumor networks governed by p53 and their
respective downstream effectors is vital to expanding our current understanding of the
fundamentals of cancer biology. To further this goal we have employed Affymetrix
microarray technology to monitor fluctuations of the MCF-7 breast carcinoma cell line's
transcriptome before and after stabilization of endogenous p53, to detect novel p53
regulated genes that may be effectors of the p53 tumor suppressor response pathway.
Briefly, MCF-7 cells expressing wildtype p53 and overexpressing both HdmX and Hdm2
(Heminger,K., Markey,M., et al. 2009) were treated with siRNA to suppress the
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expression of these critical negative regulators. By lowering transcript levels of HdmX
and Hdm2, the inhibitory control over p53 by these proteins is relaxed, thus leading to the
activation of p53’s transcriptional activity. Following data mining and statistical analysis
of gene expression data, a list of genes upregulated after downregulation of HdmX/2 and
subsequent stabilization of p53 protein levels, was generated. The complete gene list can
be obtained from Heminger et al. (Heminger,K., Markey,M., et al. 2009). Genes
selected for further validation as putative p53 targets included YPEL3.
The primary goal of part one was to validate YPEL3 as a potential transcriptional
gene target of p53 and identify any biological functions within the realm of molecular
regulation over neoplastic genesis or attenuation of malignant transformation by
mechanisms such as apoptosis, cell cycle arrest or senescence. By accomplishing this, a
more comprehensive understanding of p53's anti-tumor pathways was gained.
Furthermore, knowledge derived from this aim may support future translational research
efforts to develop therapeutically viable treatment and screening options that exploit the
potential tumor suppressive characteristics inherent in the YPEL3 protein.
MATERIALS AND METHODS
Plasmids and Transfections
Transient transfections were carried out using Lipofectamine or Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions, with regard to suggested
cell plating density, DNA amounts and lipid: DNA ratios.
For exogenous expression of p53— pcDNA3.1-p53 was utilized in RT-PCR studies
and reporter assays. pcDNA3.1-p63γ and pcDNA3.1-p73α expression vectors were both
11

generous gifts from Dr. Madhavi Kadakia (Wright State University). pcDNA3.1(constitutively active) caAKT and pcDNA3.1-(kinase dead) kdAKT were kind gifts from
Dr. Lindsay Mayo (Indiana University). The pGL3-BASIC vector (Promega) was used in
all luciferase-based reporter assays. The synthetic luciferase reporter plasmid PG13-luc
was used as a measure of p53 transactivation potential. It contains 13 copies of the p53
consensus sequence and was obtained by subcloning the promoter sequence from
pG13CAT into pGL3-BASIC. The Gateway Viral Power Cloning System containing
pLenti4-T/O-V5-DEST and pENTR/SD/D-TOPO vectors was purchased from
Invitrogen.
The YPEL3 promoter region was identified by comparing the YPEL3 reference
sequence (NCBI) to the YPEL3 genomic sequence from the University of California
Santa Cruz (UCSC) genome browser. Putative p53 consensus binding sites were located
across a ~10,000 bp stretch upstream of the YPEL3 gene which also includes the first
exon and intron using p53MH—a p53 binding site search algorithm (Hoh,J., Jin,S., et al.
2002). Three potential sites were located in a 1506 bp (-1386 to +120) region of the
YPEL3 promoter. This region was amplified using Platinum Pfx polymerase (Invitrogen)
from BAC clone RP11-114A14 (BACPAC Resources Center) and subcloned into pCRBLUNT-II-TOPO vector using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen). The
YPEL3 promoter element of interest was then isolated using KpnI and XhoI and
directionally subcloned into pGL3-BASIC. Oligonucleotides possessing the p53 response
element were synthesized, annealed and directionally cloned into pGL3-BASIC. In
addition a triple mutant was created with critical C/G residues mutated in each of the
three conserved p53 binding half sites. Finally, a scrambled sequence mutant was created.
12

All reporter constructs were confirmed by DNA sequencing analysis.
The tetracycline-inducible (tet-on) lentiviral YPEL3- V5-tagged expression
construct was designed by cloning the YPEL3 ORF into pENTR/SD/D-TOPO and then
into the pLenti4-T/O-V5 DEST vector via the Gateway cloning system (Invitrogen).
Lenti-FOXO3a-ER TM was created by subcloning the FOXO3a-ER fusion open reading
frame from HA-FOXO3a TM-ER into pENTR-TOPO and subsequently recombining this
construct with plenti4 lentiviral vector using Gateway recombination technology
(Invitrogen). FOXO expression vectors including HA-FOXO3a TM-ER (Addgene
plasmid 8353), FLAG-FOXO3a WT (Addgene plasmid 8360), FLAG-FOXO3a TM
(Addgene plasmid 8361) were all kind gifts from Michael Greenburg through the
Addgene repository (www.addgene.org)(Brunet,A., Sweeney,L.B., et al. 2004, Tran,H.,
Brunet,A., et al. 2002). FLAG-Foxo4 (Addgene plasmid 17549) and pcDNA3 and Flag
FKHR AAA mutant (FOXO1 TM, Addgene plasmid 13508) were generous gifts from
Domenico Accili and Kunliang Guan, respectively (Tang,E.D., Nunez,G., et al. 1999).
RT-PCR
Total RNA was isolated using the e.Z.N.A. Total RNA kit (Omega Bio-Tek)
according to the manufacturer’s instructions. RNA quality and quantity was assessed on
a RNA nanochip (Agilent Technologies). One microgram of total RNA was used as a
template for cDNA synthesis using the reverse transcriptase core reagent kit (Applied
Biosystems). Taqman based PCR was performed in triplicate using Assay on Demand
probe sets (Applied Biosystems) and an Applied Biosystems 7900 Sequence Detection
System. GAPDH was used as an endogenous control.
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Cell Lines
All cell lines were maintained at 37 degrees Celsius in a 5% carbon dioxide
environment. All cell lines with the exception of 76ntert and MCF10A cells were grown
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with either 10% fetal
bovine serum (FBS) or 10% neonatal calf serum (NCS) and 50 µg/ml gentamycin sulfate.
MCF10A and 76Ntert immortalized mammary epithelial cells were grown in Mammary
Epithelial Growth Medium (Lonza) supplemented with a Clonetics MEGM BulletKit
containing the following supplements: recombinant epidermal growth factor (rEGF),
insulin, 50 µg / ml gentamycin, bovine pituitary extract (BPE), hydrocortisone and 100
ng/ml Cholera toxin. Each BulletKit contained pre-aliquoted amounts of each supplement
that would establish 1X concentrations after dilution in 500 ml of MEGM base media.
H1299 cells were derived from non-small-cell lung carcinoma devoid of p53 and
have undetectable levels of p63γ. U2OS osteosarcoma cells and MCF7 breast carcinoma
cells all express wild-type p53. In addition, MCF7 cells express high levels of Hdm2 and
HdmX. HCT116 +/+ and -/- p53 colon carcinoma cell lines are isogenic with the
exception of p53 status. SAOS-2 cells were derived from an osteosarcoma and are a p53
null cell line. MCF10A cells are immortalized mammary epithelial cells derived from
human breast reductions. All of these tumor lines were purchased from the American
Type Culture Collection. 76ntert immortalized mammary epithelial cells also express
wild-type p53 and were a generous gift from Dr. Vilma Band (University of Nebraska).
Reporter Assays
H1299 cells were plated at 40-60k cells per well in 12 well plates 24 hours prior to
14

cotransfection of YPEL3-luc (250 ng), Renilla-luc (2.5-15 ng) and respective
overexpression vector (10 ng – 1 µg). The following day, cells were lysed on the plate
using 1X passive lysis buffer (Promega) and analyzed by Dual Luciferase Assay Kit
(Promega) according to the manufacturer’s instructions. All experiments for each
treatment were performed in triplicate. Error bars show variation as the standard
deviation of each set of biological triplicates. Statistical significance was determined by
using the paired student’s t-test (Sigma Plot).
DNA Damage Experiments
Twenty-four hours prior to treatment with Bleomycin, 76ntert immortalized
mammary epithelial cells were seeded at a density of 150k cells/6cm plate. The following
day the plates were treated with increasing doses of Bleomycin. Twenty-four hours later
cells were harvested. HCT116 cells either containing wildtype p53 or that were p53-null
were plated at 200k cells/6 cm plate. Twenty-four hours after plating, cells were treated
with 0.5 µg/mL Doxorubicin and harvested at 0 hr, 2 hr, 6 hr and 24 hours post-treatment.
MCF7 cells were plated at 250k cells/6cm plate. Cells were irradiated with 0 or 500 J/m²
UVC (Stratalinker). Twenty-four hours after irradiation cells were harvested. Total RNA
was extracted from the harvested cells and gene expression analyzed by RT-PCR.
Lentiviral Production and Colony Formation Assay
Lentiviral vectors were produced by cotransfection of 293FT cells with pLentiYPEL3
and lentiviral packaging mix (Invitrogen) according to the manufacturer’s

instructions. Lentivirus-containing supernatant was harvested at 48 hours after

transfection, purified by centrifugation and stored at -800C. MCF7 and U2OS cells
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containing Tetracycline Repressor (100,000 cells/well) were transduced with LentiYPEL3 or left untreated and were incubated in complete medium for 24 hours.

Infections were carried overnight in the presence of 4 µg/mL Polybrene (Sigma).

Following infection, cells were treated with tetracycline for 14 days and then stained
with 40% methanol /1% crystal violet stain.

MCF10A Transformation-Colony Formation Assay

MCF10A immortalized mammary epithelial cells were reverse-infected overnight
by plating 200K cells in 6-well plates 8 µg/ml polybrene and differing combinations of
the following shRNA expressing lentiviruses: plenti4-shp53, plenti6-RAS, plenti6-GFP,
misson-shYPEL3 all at MOIs of 2. Cells were permitted to grow for 4 weeks with
complete MEG media changes every three days. Random images were captured of each
monolayer using an Olympus 1X70 fluorescence microscope using phase contrast on day
5 and day 10 after infection. After 31 days, plates were stained with 1% crystal violet/
70% methanol for 5 minutes followed by 6 washes with 1X PBS and then photographed.
Senescence Associated beta-Galactosidase Staining

U2OS cells stably expressing the Tetracycline Repressor and Tetracycline inducible
YPEL3 or LacZ were induced with 1 mg/mL Tetracycline for 6-7 days. Cells were
processed with the Senescence beta-Galactosidase Staining Kit, Cell Signaling
Technology according to the manufacturer’s instructions and visualized on an Olympus
1X70 fluorescence microscope.
16

RESULTS
p53 induces an upregulation of YPEL3 gene expression.

Ectopic expression of p53 induces YPEL3 gene expression.

In order to determine if YPEL3 is a direct target of p53, it is expected that an
increase in expression would be seen in the presence of exogenous p53. To test this,
U2OS osteosarcoma cells were transfected with pCMV 3.1A-p53 expression vector or
vector alone and then assessed by quantitative PCR (qPCR) 24h later.
U2OS cells demonstrated an increase in YPEL3 gene expression twenty-four
hours after being transiently transfected with p53 (Figure 1A, black bars). Expression
levels of the p53 target gene—cyclin dependent kinase inhibitor 1A (CDKN1A) or p21,
was also monitored as an indicator for p53-depedent transactivation. As anticipated, p21
expression demonstrated a similar increase in expression resulting from p53
overexpression.
In addition to examining the effect of p53 on YPEL3 expression, the p53 family
of transcription factors includes other members such as p63γ and p73α 10 that play roles in
the molecular regulation of epithelial differentiation and the cellular stress response,
respectively (Murray-Zmijewski,F., Lane,D.P., et al. 2006). These genes encode
transcription factors that can bind to and transactivate DNA sequences similar to the p53
consensus binding site and can thus act to regulate transcription of several established
10
The following p63 isoforms exist: p63TA, ΔNp63, p63 α, p63 β and p63γ in mice and humans. p73 has at 28 different isoforms (α,
β, γ, δ, ε, ζ, η) each retaining the full length protein (TA), missing exon 2, missing exon 2/3, or missing the entire N-term
transactivation domain, ΔN. The TA isoforms of both proteins typically are the strongest transactivators. The ΔN isoforms can acts as
dominant negatives to the TAs and thus may act as oncogenes ( Murray-Zmijewski,F., et al, 2006).
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p53 target genes (Murray-Zmijewski,F., Lane,D.P., et al. 2006, Ozaki,T. and
Nakagawara,A. 2005, Sbisa,E., Catalano,D., et al. 2007). Therefore, it was of interest to
determine if these proteins could activate YPEL3 gene expression. To test this, p63γ—
the strongest transactivator of the p63 isoforms, and p73α—a p73 isoform that is
normally induced in response to genotoxic stress (Ozaki,T. and Nakagawara,A. 2005)
were transfected into U2OS and H1299 cells, respectively. As anticipated from the
results obtained with overexpression of p53, introducing p63у or p73α resulted in an
increase in YPEL3 gene expression—further extending the scope of regulation of YPEL3
gene expression to all three p53 family members ( Figure 1A-C). Interestingly, based on
this result, there may be a link between p63 regulation of epithelial differentiation and the
YPEL family, in particular regarding YPEL1 and its role in mesynchemal to epithelial
differentiation (see introduction and YPEL3 background section) (Candi,E., Cipollone,R.,
et al. 2008, Farlie,P., Reid,C., et al. 2001).
YPEL3 gene expression is altered in response to genotoxic stress through activation of
endogenous p53.

The p53 protein is stabilized as a result of DNA damage-dependent genotoxic stress in
order to facilitate cell cycle arrest and DNA repair; although apoptosis or cellular
senescence may occur if damage is severe and sufficient repair is not achieved (elDeiry,W.S. 1998). These cellular defense mechanisms governed by p53 protect the cell
from accruing genetic mutations that could potentially increase the risk of neoplastic
transformation (see Introduction and p53 background section for a more detailed
discussion). To determine if YPEL3 transcription is induced in response to DNA
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damage, tumor and immortalized cell lines were treated with a range of doses of
chemotherapeutic drugs bleomycin or doxorubicin (76nTERT mammary epithelial cells
and HCT116 +/+ p53 colon carcinoma cells, Figure 2 and 3), UVC irradiation (MCF7
and 76nTERT mammary epithelial cells, Figure 4) or a doxorubicin time course (HCT116
colon carcinoma cells, wildtype and p53 null, Figure 5). After treatment, all cell types
were processed by RT-PCR analysis to assess YPEL3 mRNA levels as well as the
expression levels of p21 or BAX—to genes established as transcriptional targets of p53.
By treating 76nTERT immortalized mammary epithelial cells with increasing doses of the
radiomimetic bleomycin, it was observed that YPEL3 mRNA increased in a dosedependent manner along with p21 and BAX (Figure 2, bottom panel). HCT116 +/+ p53
cells treated with doxorubicin demonstrated a robust dose response elevation of YPEL3
and p21 mRNA levels (Figure 2, top panel). Endogenous YPEL3 protein was also
observed to increase in HCT116 cells +/+ p53 after doxorubicin treatment (Figure 3).
Additionally, ultraviolet radiation (254nm UVC, 0-500 J/m²) elicited a similar elevation
of YPEL3 mRNA expression in 76nTert mammary epithelial cells (Figure 4, bottom
panel). MCF7 cells were also treated with UVC, and at a relatively high dose of 500 J /
m² compared to doses used with 76nTert cells, only a two fold increase in YPEL3
transcript was observed (Figure 4, top panel). This may be because the p53 response to
DNA damage in MCF7 cells is dampened due to the overexpressed levels of HdmX and
Hdm2 (Heminger,K., Markey,M., et al. 2009) compared to breast epithelial cells.
To determine if p53 was required for the DNA damage-dependent increase in
YPEL3 transcript, HCT116 colon carcinoma cells that are isogenic with the exception of
p53 expression status were treated with the DNA damaging agent doxorubicin (Figure 5).
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At several time points, samples were collected and analyzed for YPEL3 and p21
expression levels. A significant temporal increase in both YPEL3 and p21 mRNA levels
was observed in the cell line containing wildtype p53 (Figure 5, left panel). However, the
same cell line null for p53 demonstrated much less of an increase in YPEL3 mRNA when
compared to the same cells expressing wildtype p53 (right panel). p21 levels increased
to a lesser degree in HCT116 -/- p53 cells at 2 and 6 hour time points compared to p53positive cells. However, after 24h hours of doxorubicin treatment both cell lines
demonstrated a similar increase in p21 levels (10-fold compared to 0h time points). It is
possible that the five-fold induction of YPEL3 transcript levels observed in p53-null
HCT116 cells after 24h of doxorubicin treatment may be the result of p73α upregulation
in response to DNA damage (Fernandez-Garcia,B., Vaque,J.P., et al. 2007). Furthermore,
endogenous p73 has been shown by other labs to be upregulated after DNA damage, in
the same cell line used in these experiments (Lokshin,M., Tanaka,T., et al. 2005). This
observation coupled with the fact that p73α overexpression triggered an increase in
YPEL3 mRNA in H1299 cells (see Figure 1C), further support a potential role for p73 in
the regulation YPEL3 gene expression.
Computational analysis of the YPEL3 promoter region reveals potential cis-acting p53
response elements.
Computational analyses of the YPEL3 promoter for DNA sequences that
resemble the consensus p53 binding site were performed using the publicly available
Figure 1. YPEL3 mRNA levels increase in response to overexpression with p53, p63
and p73.
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A. U2OS cells were transfected with 125 ng of pcDNA3.1-p53 (p53) or an equivalent
amount of pcDNA3.1A (vector). B. U2OS cells were transfected with 1 µg of pcDNA3.1p63g-GST. C. H1299 cells were transfected with 125 ng pcDNA3.1-p73a or an
equivalent amount of pcDNA3.1A (vector). Cells were harvested 24 hours after
transfection and YPEL3 and p21 RNA levels analyzed by RT-PCR using GAPDH to
normalize against. Y-axis is the relative fold change normalized to vector-only transfected
cells. Error bars represent the 95% confidence interval of PCR replicates each in
triplicate.

21

22

Figure 2. YPEL3 mRNA increases in a dose dependent manner in response to
DNA damage.
HCT116+/+p53 cells were exposed to increasing doses of doxorubicin (0-0.5 μg/mL)
for 24h (top panel). 76NTert mammary epithelial cells were exposed to Bleomycin
(0-0.1 units/mL) for 24 hours (bottom panel). YPEL3 and p21 mRNA levels were
assayed by RT-PCR and normalized to GAPDH mRNA levels. Error bars represent
95% confidence intervals.

23

24

Figure 3. Endogenous YPEL3 protein levels increase in response to DNA
damage.
Endogenous YPEL3 (top panel) and p53 (bottom panel) protein levels increase in
HCT116+/+p53 cells exposed to 0.4 μg/mL doxorubicin for 40 hours (compare
untreated (-) to doxorubicin treated (+)). shYPEL3 represents HCT116+/+p53 cells
transduced with a shYPEL3 expressing lentivirus. (Western blot performed by Dr.
Berberich)
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p53MH algorithm (Hoh,J., Jin,S., et al. 2002). This program uses the p53 consensus
binding sequence (Transfac database, PMW(position weighted matrix) M273,
RRRCA/TA/TGYYY ---0-14N--- RRRCA/TA/TGYYY) to search a DNA sequence for
potential p53 binding sites matching the consensus binding site (el-Deiry,W.S., Kern,S.E.,
et al. 1992). Several binding sites were located both directly adjacent to and overlapping
the transcription start site of the gene (see Figure 6A), thus justifying further experiments
such as luciferase reporter analysis and chromatin immunoprecipitation of this region of
the YPEL3 promoter for p53 binding. Using this algorithm, another site with 80%
homology to the p53 consensus was also found ~1400 base pairs 5ʹ of the transcription
start site. Shortly after identification of these potential p53 binding sites, a database, p53
FamTaG, containing an in silico global promoter map of all known human genes
containing potential p53 response elements coupled to microarray data containing p53,
p63 and p73 overexpression-mediated gene expression modulations of the human
transcriptome was published online (Sbisa,E., Catalano,D., et al. 2007). YPEL3 was
included in the database under genes that were found to be elevated as a result of the
overexpression of p53 and p63—supporting data reported in Figure 1. In addition, two
p53 response elements were listed in the in silico database; however, ChIP primers
(Figure 12) that I designed to target each site failed to demonstrate that p53 actually
interacted with either of the two (computationally determined) response elements (data
not shown).
Reporter Analysis of the YPEL3 promoter. A 1506 bp region of the YPEL3 promoter
region including both potential p53 binding regions was cloned using a BAC clone
(BACPAC database., Oakland, CA Accession # RP11-455F5) containing a ~200kb region
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Figure 4. YPEL3 mRNA increases in response to UVC irradiation.
MCF7 cells were treated without and with 500 J / m² UVC radiation (top panel). 76nTert
mammary epithelial cells were irradiated with increasing doses of UVC (0, 25, 50, 250,
500 J / m²) (bottom panel). Twenty-four hours following irradiation, YPEL3 and p21
mRNA levels were assessed by qPCR. Error bars represent the 95% CI.
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Figure 5. The DNA damage-dependent increase in YPEL3 mRNA expression is p53
dependent in HCT116 colon carcinoma cells.
(A) HCT116 +/+ p53 and (B) HCT116 -/- p53 were exposed to 0.5 μg/mL of
doxorubicin and total RNA extracted at the indicated time point. YPEL3 (black bars) and
p21 (grey bars) mRNA levels were assayed by RT-PCR. All gene expression values were
normalized to GAPDH expression. Error bars represent 95% confidence intervals. (C)
Western blot analysis of p53 protein levels following a treatment with 0.5 μg/mL of
doxorubicin for the indicated time points. As expected Hct116+/+ p53 cells show a
dramatic induction of p53 protein while Hct116-/-p53 cells show no detectable p53
protein.
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of chromosome 16 including the YPEL3 gene and 5ʹ region upstream as a PCR template.
This region was cloned into the PGL3-Basic luciferase reporter construct, effectively
placing the luciferase gene under transcriptional control by the 1506 base pair region of
the YPEL3 promoter (Figure 6A). The YPEL3 1506 bp reporter construct was tested in
the presence of exogenous p53 for activity by cotransfection into p53-null cell lines
(H1299 and HCT116-/- p53) with pCMV3.1A-p53. An increase in relative luciferase
activity was observed with increasing amounts of p53 in both cell lines (Figure 6B).
PG13-luc, a synthetic p53-responsive reporter harboring thirteen p53 consensus-binding
sites was used as a positive control to indicate that p53 transactivation occurred.
As previously alluded to, it has been established in the literature that p53 family
members such as p63γ can also transactivate known p53 transcriptional targets (MurrayZmijewski,F., Lane,D.P., et al. 2006). Therefore, YPEL3 promoter driven-luciferase
activity was examine in the presence of overexpressed p63γ. Indeed, a significant
increase in luciferase activity was observed with increasing amounts of p63γ expression
vector cotransfected into H1299 cells (Figure 7). Furthermore, p63γ overexpression is
not cytotoxic at high doses compared to p53. Thus, ten times more p63γ vector was able
to be transfected into cells than p53 to elicit a robust >70 fold increase in luciferase
activity after 24h. This finding provides support for previous observations that p63
overexpression leads to the induction of endogenous YPEL3 expression (see Figure 3B).
To determine the contribution of each binding site in response to exogenous
p53, a deletion analysis was performed whereby truncation mutants of the 1506 bpYPEL3-reporter construct were engineered to isolate and test suspected binding sites.
32

Two deletion mutant reporters were cloned. They are referred to as the “5ʹ-deletion
mutant” and “3ʹ-deletion mutant”—denoting that the 5ʹ or 3ʹ terminus of the YPEL3
promoter was removed from each, respectively (Figure 8, top panel). Each of these
reporters was cotransfected with p53 (center panel) or p63γ (bottom panel) expression
vectors and cellular extracts were assayed 24h later. From these experiments, it was
observed that the 5´-deletion mutant retained similar luciferase induction profiles as
wildtype in response to ectopic p53 or p63. The 3´-deletion mutant however, lost all
luciferase induction potential. This was expected because it did not retain any potential
binding sites. Therefore, it was concluded that the 3ʹ response element (retained in the
5ʹtruncation mutant reporter), encompassing the transcription start site was responsible
for the elevation of luciferase activity resulting from transfection of either p53 or p63γ.
The 605 bp 5-deletion mutant, containing the suspected p53-binding site was
also tested for luciferase activity after DNA damage-dependent p53 induction. HCT116
colon carcinoma cells expressing p53 were transiently transfected with the YPEL3 605
bp reporter and treated twenty-four hours later with doxorubicin. A 2-fold elevation in
luciferase activity was observed in response to p53 activation by DNA damage resulting
from doxorubicin treatment (Figure 9)—indicating that this region of the YPEL3
promoter also contained an element that was responsive to genotoxic stress.
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Thus, this element was hypothesized to be responsible for the DNA damage-dependent
increases in YPEL3 gene expression observed in Figures 2-5. To further examine this
site, a 3ʹ 50 bp response element containing all three half sites was cloned into PGL3Basic (Figure 10, top panel). Two additional mutant reporters were also constructed. The
C and G nucleotides required for p53 binding located at the 4th and 7th position of each 10
bp half site, respectively, were changed to either A or T. Only critical nucleotides
necessary for p53 binding were changed while preserving the remaining sequence of the
response element to facilitate a more conservative approach (compared to deletion
analysis) to test p53-dependent transactivation of this site. The second mutant construct,
containing a scrambled 50-base pair sequence was employed as an additional negative
control in that it should also not be able to bind p53. All three reporters were tested by
contransfection with increasing amounts of p53 expression plasmid into H1299 cells to
demonstrate the preferential binding and transactivation of p53 at this potential binding
site. The wildtype 50 bp reporter elicited a dose-dependent response to increasing
amounts of p53, whereas both of the mutants showed no increase in activity (Figure 10,
bottom panel). This result demonstrated that p53 could induce transcription dependent
on a 50 bp region of the YPEL3 promoter containing three adjacent half-binding sites
matching the core p53 consensus-binding element.
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Figure 6. The YPEL3 promoter contains a p53 response element.
(A) a 1.5 kilobasepair region of the YPEL3 promoter spanning -1386 to +120 relative to
the start site of transcription was cloned upstream of a firefly luciferase reporter gene
(YPEL3-luc). The asterisks represent putative p53 half-sites as determined by analysis of
the promoter sequence with the p53MH algorithm. The location of the three p53-half
sites found searching the promoter sequence with p53MH is shown along with the
percentage of conservation to the p53 consensus binding site. Bolded nucleotides are
critical to maintaining the binding affinity of the response element to p53. (B) YPEL3luc activity (gray bars) and PG13-luc activity (black bars), used as a positive indicator for
p53 transactivity were increased in H1299 (center panel) and Hct116 -/- p53 (bottom
panel) when cotransfected with a human p53 expression vector. Luciferase activity from
both reporters was normalized by cotransfection with pCMV-Renilla-Luc. Each assay
was performed in triplicate and error bars represent the standard deviation of the mean.
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Figure 7. p63γ can activate the YPEL3 promoter reporter gene.
Increasing amounts of p63 γ expression vector were cotransfected with the 1506 bp
YPEL3 luciferase reporter or vector only. Luciferase values were determined 24h after
transfection and normalized to CMV Renilla-luc to control for variation of transfection
efficiency.
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Figure 8. Deletion analysis of the YPEL3 promoter.
Five and three prime deletion mutants of the 1506 bp YPEL3 promoter luciferase
reporter were cloned by removal of segments by specific restriction digest and
recircularization of the linearized vector. Arrows represent potential p53 binding sites
(Top panel). Overexpression experiments with either p53 (center panel) or p63γ (bottom
panel) were performed to determine which deletion mutant still contained a functional
p53-binding site.
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Figure 9. The YPEL3 promoter contains a DNA-damage response element.
A truncation of region of the YPEL3 promoter spanning -486 to +120 was subcloned
into the pGL3-basic luciferase reporter vector. The reporter was transfected into
Hct116 cells harboring wild-type p53 and then subjected to DNA damage by
doxorubicin treatment for 24 hours prior to firefly luciferase analysis. Normalization
was performed by cotransfection with a pSV40-beta-galacosidase plasmid and
assaying cell lysates for beta-Galactosidase enzymatic activity
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Figure 10. The core p53 binding region required for YPEL3 transcriptional
activation consists of three sequential 10 bp half sites.
A 50 bp region containing the three putative p53 half sites overlapping the YPEL3
transcription start site was cloned into the pGL3-Basic luciferase reporter construct.
Arrows represent each half site and gray blocks represent exons 1 and 2. The p53
response element is boxed and nucleotides of each half-site are in bolded and labeled
below each respective site. Nucleotides conserved with the p53 consensus sequence are
capitalized (top panel, cartoon). The wild type YPEL3 50bp reporter (black bars), a 50 bp
triple mutant where each half site harbored mutations at the critical C and G residues at
the 4th and 7th position of each half site (grey bars) and a reporter containing a 50 bp
scrambled sequence (white bars) were each cotransfected with renilla luciferase plasmid
and increasing amounts of p53 plasmid. Relative luciferase activity represents firefly
luciferase light units over renilla luciferase light units for each sample. Error bars
represent standard deviation of the mean of three biological replicates. The Western blot
shows the level of p53 protein for each transfection. The western blot below
demonstrates that p53 protein expression increased with increasing amounts of plasmid
cotransfected. (Luciferase experiment and Western blot performed by Amber Todd.)
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Caution must be exercised when deleting portions of promoter DNA from a
luciferase reporter while attempting to identify cis-acting enhancer elements. It is
necessary to ensure that basal transcriptional activity of the mutated reporter gene is not
inadvertently lost during deletion analysis—possibly yielding false positive results. In
other words, by deleting regulatory regions around the transcription start site of the
YPEL3 luciferase reporter may block luciferase transcription entirely by inadvertently
destroying the YPEL3 promoter transcription start site. Thus loss of transactivation by
the response element that is responsible for p53 dependent activation of YPEL3 promoter
may only really just be the result of losing all basal reporter transcription. In order to
address this concern, the luciferase activity of YPEL3 50 bp-luc, YPEL3 50 bp triple
mutant-luc, and YPEL3 1506 bp-luc (wildtype) were measured in response to p53
overexpression and graphed relative to each other along with the empty vector—to
provide an indication of promoterless-baseline expression ( Figure 11). An additional
site-directed mutant was designed, referred to as “1506 bp-luc site-directed,” where the
4th C and 7th G of the central p53 half site were mutated to A and T, respectively. This
construct was also assayed in the presence of increasing amounts of p53 expression
vector along with the other four previously discussed reporters. As previously observed,
both wildtype YPEL3 luciferase reporters (1506 bp-luc and wt50bp-luc) showed p53dependent increases in luciferase activity that paralleled the amount of p53 cotransfected
(Figure 11). The mutant reporters, however, did not respond to the presence of ectopic
p53—indicating that mutated nucleotides within the suspected p53 binding site are
indeed critical for transactivation of the YPEL3 promoter by p53. The basal promoter
activity of both mutants was still maintained compared to the activity generated by the
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pGL3-BASIC empty vector, albeit at a lower level when comparing each to its respective
wildtype reporter.
Although luciferase reporter analysis is a powerful technique for assessing the
transactivation potential of a particular transcription factor on a specific DNA sequence,
it is less than perfect in that a disruption of the genomic region of DNA under scrutiny
from its chromosomal environment occurs after cloning it into a luciferase vector.
Transcriptional effects of other elements adjacent to the cloned region of DNA being
analyzed are not taken into account during the analysis. In addition, promoter regulation
is constantly being affected by epigenetic mechanisms. In vivo, promoter methylation
acts to silence gene expression along with chromatin remodeling complexes which can
modify histones and alter interactions with nuclear scaffolding (Robert Weinberg, The
Biology of Cancer, 2006). This can change local chromatin architecture in the vicinity of
the promoter region—affecting the accessibility of transcription factor binding sites by
compatible transcription factors. The effects that these processes have on regulation of
transcription cannot be accounted for by solely relying on luciferase reporter studies.
Therefore, in order to explore p53 interactions with the genomic YPEL3 promoter in
vivo, chromatin immunoprecipitation was employed.
Endogenous p53 binds to the YPEL3 gene promoter in vivo in response to DNA
damage.
Chromatin immunoprecipitation or ChIP allows the investigator to probe trans-acting
factor interactions within specific DNA regions while maintaining the genomic
architecture of the region of DNA under study. Briefly, formaldehyde-crosslinked,
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Figure 11. p53-dependent activation of the full length YPEL3 promoter is inhibited
by site-directed mutagenesis of the central p53 half-site.
H1299 cells were transfected with 200 ng of each luciferase reporter, 1ng of Renilla-luc
and increasing amounts of p53 plasmid (2.5-20ng) in 24 well plates. To demonstrate that
each of the YPEL3 mutant reporters (1506 bp site directed mutant-luc and 50 bp-triple
half site mutant-luc) maintained some degree of basal promoter activity, pGL3-BASIC
empty vector is provided for comparison. Error bars represent the standard deviation of
the mean of biological triplicates.
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sonicated chromatin (300-500 bp) was isolated from HCT116 colon carcinoma cells
expressing wildtype p53 treated with and without doxorubicin to induce endogenous p53
stabilization and activation. Chromatin fragments covalently complexed with p53 protein
were isolated using a combination of anti-p53 Ab-1 antibody and protein G-coupled
magnetic beads. After washing and crosslink reversal, the resulting chromatin samples
were analyzed by polymerase chain reaction (PCR). In order to assess potential
interactions of endogenous p53 protein with the suspected p53 binding site (see Figure
10, top panel) present in the YPEL3 promoter region, primer pairs used in PCR were
designed to probe this triple half-site (Firgure 12, cyan rectangle and yellow triangle) and
several other regions with sequences that matched the p53 consensus above a threshold of
60% (Figure 12, red triangles) throughout a 5 kb region of the YPEL3 gene and promoter
region.
Consistent with earlier luciferase reporter results, ChIP analysis shows that p53 is
bound to the YPEL3 promoter in response to DNA damage-dependent genotoxic stress
(Figure 13). This is evidenced by the detection of PCR product specific to primer pairs B
using chromatin immunoprecipitated with p53 antibody from doxorubicin-treated cell
lysate as a template for PCR amplification. Primer pair B encompasses a region 315 base
pairs upstream of the (3ʹ) p53 consensus site identified from luciferase-based reporter
studies. Primer region B was the closest region to the suspected p53 binding site that was
non-GC rich and thus consistently compatible with PCR reaction conditions required to
obtain a single reaction product. To demonstrate the specificity of p53 interacting with
this specific region of DNA adjacent to YPEL3 transcription start site, primers pairs “A”
(upstream), and “C” (downstream) as well as a pair designed to span a region next to the
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Figure 12. DNA regions of the YPEL3 gene examined by chromatin
immunoprecipitation (ChIP).
The transcription start site is denoted by the bent arrow at the 5´end of exon 1. All exons
are highlighted in green. Regions amplified by PCR in the ChIP experiment are
highlighted by orange arrows. Larger red triangles mark potential p53 binding sites
reaching a threshold of at least 60% similarity to the p53 consensus binding site. The
smaller red triangles flanking each orange arrow (PCR product) represent individual
primers. Primer pair 13 and 7 correspond regions A and C, respectively which were used
as negative controls. Region B was amplified by primer set 4 and is located
approximately 400 base pairs downstream from the transcription start site and p53
binding site cluster (cyan rectangle). A potential p53famTaG site included in the
analysis is located in the 5’ promoter region, upstream ~1000 bp from the YPEL3
transcriptional start site and is labeled in blue font. It is encompassed by the negative
control primer pair targeting region A in Figure 13.
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Figure 13. In response to genotoxic stress endogenous p53 protein is able to bind
directly to the YPEL3 promoter region in vivo.
Chromatin immunoprecipitation assays were performed using undamaged or doxorubicin
treated HCT116 +/+ p53 cells. Crosslinked chromatin was immunoprecipitated with p53
or IgG negative control antibodies. After crosslink reversal, PCR products were
generated from chromatin from each treatment condition (untreated and doxorubicin
treated) using primers specific to regions A, B and C. “In” denotes amplification of
input chromatin before immunoprecipitation to demonstrate that equivalent amounts of
chromatin were immunoprecipitated and all primers pairs are functional.
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GAPDH gene, which does not contain any p53-binding consensus sites were tested. As
anticipated, amplification using these negative control primers failed to demonstrate any
enrichment for p53 binding neither before nor after Doxorubicin treatment (Figure 13).
All of the other primer pairs (see Figure 12) that encompassed other potential p53 binding
sequences failed to demonstrate any enrichment with doxorubicin treatment (data not
shown).
Human YPEL3 induction inhibits cellular proliferation of tumor cells through
induction of cellular senescence.
Induced expression of exogenous YPEL3 results in a decrease in colony formation in
breast and bone cancer cells.

As discussed previously, expression of exogenous murine YPEL3 has been
shown by S. Baker to inhibit proliferation of mouse myeloid precursor cells (S. Baker,
2003). This study demonstrated that 32Dcl3 myeloblastic cells stably expressing an
inducible YPEL3 construct, resulted in a modest increase (~11%) in the detection of
apoptotic cells evident in the YPEL3-induced cells compared to controls, as determined
by Annexin V-based flow cytometry (see YPEL3 background section). Considering the
fact that mouse and human YPEL3 are 100% identical in amino acid composition, human
YPEL3’s biological activity was assayed in human cell lines to determine if the growth
suppressive phenotype observed in mouse was conserved in human cells. The wildtype
YPEL3 open reading frame (ORF) sequence was cloned into the pENTR-TOPO-D/SD
directional gateway shuttling vector (Invitrogen) using pSPORT6-hYPEL3 cDNA (Open
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Biosystems) as PCR template. To facilitate lentiviral infection and controlled induction
of YPEL3 expression in tumor and normal cell lines, LR-clonase-mediated transfer of the
YPEL3 ORF from the pENTR shuttling vector into a lentiviral expression vector was
performed. This vector also contained a tetracycline operator (tet-on)-regulated CMV
promoter to allow for regulated induction of YPEL3 expression and a C-terminal V5
epitope tag to detect ectopic YPEL3 protein levels with anti-V5 antibody. To allow for
the creation of cell lines stably expressing YPEL3, this construct also confers resistance
to the eukaryotic antibiotic Zeocin.
This expression system was tested in U2OS and MCF7 cell lines stably
expressing the tetracycline repressor gene. Both cell lines were infected and then grown
either with or without tetracycline for 14 days while under constant selection with
Zeocin. After this time had elapsed, a reduction in both the size and number of colonies
formed by the YPEL3-expressing clones compared to those not stimulated by tetracycline
to induce YPEL3 expression was evident in both cell lines tested (Figure 14A -C).
Levels of YPEL3 mRNA reached just under 10 fold that of controls without addition of
tetracycline (Figure 14C, top panel) which is well within the physiological range of
expression normally seen downstream of p53 dependent activation in response to
genotoxic stress (see Figures 2-5).
To further validate this anti-proliferative effect, a resazurin-based cell viability
assay (CellQuanti-Blue™) was used to assess the effect that induction of YPEL3 had on
cell viability. The redox dye resazurin was added to cells that had been treated with
tetracycline for 24h to induce YPEL3 expression. This compound is internalized and
reduced only by viable, metabolically active cells to a fluorescent product resorufin.
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Fluorescence can then be analyzed spectrophotometrically, providing a quantitative
means to evaluate cell viability fluctuations resulting from induced expression of YPEL3.
A decrease in the overall viability of cells induced to express YPEL3 compared to lacZ
expressing controls was apparent after only twenty-four hours in tetracycline-containing
media (Figure 14D). This data provides compelling evidence that YPEL3 functions as a
growth suppressive gene when expressed in human tumor cells. After determining that
YPEL3 expression in human cells caused a growth suppressive phenotype that was
similar to that observed in mouse, it was of interest to determine the mechanism of this
suppression. However, after performing an extensive analysis to determine if YPEL3
induction in human bone and breast tumor cell lines would result in apoptosis, there was
no detectable difference in apoptotic induction indicated by caspase-3 dependent PARP
cleavage and flow cytometry examining the apoptotic subG1 peak (data not shown). It is
still possible that murine YPEL3 (SUAP)-dependent programmed cell death observed by
S. Baker is either species or cell type specific. Further, endogenous mYPEL3 expression
was also observed by S. Baker to be upregulated in response to interleukin-3 removal
from mouse myeloblastic cells triggering differentiation into granulocytes and subsequent
apoptosis. This is an indication that YPEL3 may be involved in the regulation of normal
hematopoiesis, including apoptotic turnover of mature granulocytes. Furthermore, it is
evident from reduced YPEL3 transcript levels in human hematologic tumors (Oncomine
Microarray data, Figure 15) compared to normal bone marrow, that YPEL3 may play a
role in the
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Figure 14. Induction of YPEL3 leads to growth suppression.
(A) Representative images of colony formation assays using MCF7TetR and U2OSTetR
cells transduced with lentivirus containing a tet-inducible YPEL3-V5 cDNA, selected
with Zeocin, and treated with and without 1 µg/mL Tetracycline (Tet). (B) Histograms of
average colony numbers from colony formation assays were repeated in duplicate
(U2OSTetR) or triplicate (MCF7TetR). Error bars represent the standard error of the
mean. (C) Top: Western blot demonstrating YPEL3 and LacZ protein expression in the
indicated cell lines. Bottom: RT-PCR analysis of YPEL3 mRNA expression in
MCF7TetR cells following treatment with tetracycline. (D) MTT assay of U2OSTetR
cells transduced with the indicated lentivirus and then treated for 24 hours with or
without tetracycline. Each condition was performed in quadruplet with error bars
representing standard error of the mean. (Colony Formation Assay performed by Kelly
R. Miller. MTT assay performed by Steven J. Berberich.)
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.Figure 15. YPEL3 expression is down-regulated in childhood leukemia tumors
compared to normal bone marrow.
Using Oncomine— an online repository of microarray data from various human tumor
studies, as in silico YPEL3 gene expression analysis of 108 bone marrow and 13
peripheral blood samples from patients with childhood acute leukemias was performed.
The box plot depicts the relative expression of YPEL3 mRNA levels from each tumor
type relative to unmatched normal bone marrow. The top and bottom of each box
represent the 75th and 25th or upper and lower quartiles, respectively. The transition
between solid black to white in each box represents the median value of YPEL3
expression. The whiskers extend to the 90th and 10th percentile. Filled dots show
positions of highest and lowest outliers. The number of patient samples for each
condition is listed below (Oncomine Human Tumor Gene Expression Repository, 2009).
N= number of patient samples for each tissue type
B-cell Acute Lymphoblastic Leukemia, N = 87
Acute Myeloid Leukemia, N = 23
T-cell Acute Lymphoblastic Leukemia, N = 11
Age matched, normal bone marrow aspirates, N = 6
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suppression of hematologic tumor formation. This was discovered while searching
Oncomine—an online database containing microarray data for numerous human cancers,
that acute myeloid leukemia, acute B-cell lymphoblastic leukemia, and acute T-cell
lymphoblastic leukemia patient samples all demonstrate significant decreases in YPEL3
gene expression compared to age-matched, normal bone marrow samples (Figure 15,
Oncomine database) (Andersson,A., Ritz,C., et al. 2007, Rhodes,D.R., KalyanaSundaram,S., et al. 2007).

Moreover, reduced YPEL3 expression may be involved in

perpetuating a blast crisis considering the acute nature of some of the above tumors
(Andersson,A., Ritz,C., et al. 2007).
In summary, apoptosis may not play a significant role in the YPEL3-dependent
growth suppressive phenotype seen in colony formation and cell viability assays
performed with human tumor cell lines by our laboratory. Nevertheless, there remains a
possibility that YPEL3-dependent apoptosis induction may be cell lineage or tissue-type
specific. YPEL3 expression may play a role in hematopoietic regulation and possibly
function as a myeloid lineage-specific tumor suppressor.
YPEL3 expression induces a G1-cell cycle arrest.
After investigating the possibility that apoptosis was the cause of decreased
proliferation of U2OS and MCF7 cells, other growth suppressive pathways in common
with the p53 tumor suppressor pathway, such as cell cycle arrest and cellular senescence
were considered. In order to determine what effect YPEL3 has on the cell cycle, U2OS
cells stably expressing a tet-inducible YPEL3 construct were induced to express YPEL3.
After five consecutive days of tetracycline-induced YPEL3 expression, G1, S, and G2/M
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cell cycle percentages were determined along with the percentage of apoptotic cells (subG1 peak) for each condition. An increase in the G1 population and decrease in S-phase
cells was seen in cells expressing exogenous YPEL3 (Figure 16). Thus, ectopic YPEL3
expression in human tumor cells induces an arrest in the G1 phase of the cell cycle.
YPEL3 induces premature cellular senescence.
Cellular senescence occurs when a cell enters an irreversible cell cycle arrest
(Vousden,K.H. and Prives,C. 2009, Xue,W., Zender,L., et al. 2007). This process can be
triggered by a variety of stimuli such as telomere shortening after many rounds of DNA
replication. This results in “replicative senescence,” a physiological process that occurs in
“aged” cells after dividing a finite number of times before reaching telomere lengths that
are prohibitive to carrying out further DNA replication. Cellular stressors in the form of
DNA damage, oxidative stress or oncogenic activation (i.e. ras-mediated senescence) can
elicit a similar form of permanent cell cycle arrest termed “premature
senescence.”(Fridman,A.L. and Tainsky,M.A. 2008) Although detailed mechanisms of
cellular senescence have not yet been completely determined, molecular pathways
involved in cell cycle regulation such as the p53/CDKN1A or Rb-regulated
cyclin/CDK/p16 growth regulatory networks appear to be necessary to trigger and
maintain senescence, respectively. (Fridman,A.L. and Tainsky,M.A. 2008). To explore
whether YPEL3 expression results in the induction of a senescent phenotype, a betagalactosidase staining 11 assay and senescence-associated heterochromatic foci detection
(SAHF) were utilized to detect senescent cells.

11

Accumulation of lysosomal beta -galactacdase is a common feature among senescent cells. The amount of enzyme present can be
assayed by treating cells with X-gal substrate under acid conditions. This compound is processed by the enzyme to yield a blue
colored product which will accumulate only in senescent cells, providing a means to identify these cells and measure this process in an
experiment al population.
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Figure 16. U2OS cells undergo a G1 arrest after induction of YPEL3 expression.
Tet repressor expressing U2OS osteosarcoma cells stably expressing either
tetracycline-inducible lacZ (negative control) or YPEL3 were induced for 5 days with
1 μg/ml tetracycline. Following treatment, cell cycle distribution, represented as the
G1 / S phase ratio of each sample (top panel), was determined by propidium iodide
staining followed by flow cytometry analysis and is represented graphically in the
lower panel.
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YPEL3 YPEL3 + tetracycline

Figure 17. YPEL3 expression triggers cellular senescence.
U20S cells stably expressing tet-inducible LacZ (left panel) as a negative control for
senescence induction or tet- inducible YPEL3-V5 (right panel) were treated with
tetracycline for 7 days and then stained Hoechst dye to visualize the nucleus and
highlight senescence associated heterochromatin foci. In addition cells were stained
for senescence associated beta-galactosidase (bright field) which is identified by a
cyan staining of the cytoplasm and nucleus. The left panel represents the percentage
of cells staining positive for beta-galactosidase activity. The right demonstrates the
percentage of nuclei containing heterochromatin foci. One-hundred cells counted for
each condition. Error bars represent the standard error of the mean of three separate
experiments. (Experiment performed by Kelly R. Miller.)
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seven days of ectopic YPEL3 induction (Figure 17). It was observed in these cell lines
expressing tet-inducible lenti-YPEL3 as well as in IMR90 normal human fibroblasts
infected with lenti-YPEL3 (data not shown), that an increase in the percentage of betaGalactosidase positive cells was apparent compared to controls expressing only lacZ or
GFP. This data strongly supports a role for human YPEL3 in mediating cellular
senescence. This is currently thought to be the primary mechanism by which YPEL3
induces a decrease in cell growth seen in colony formation assays. Further, experiments
have shown that endogenous YPEL3 is necessary for RAS-mediated senescence; a
process that is also dependent on the functional p53 (Kelley, Miller, et al, 2010). Even
more surprising is the recent observation that ectopic YPEL3 expression can rescue the
senescent phenotype in the presence of RNAi targeting p53 (Kelley, Miller, et al, 2010).
Attenuation of endogenous YPEL3 expression results in a transient loss of contact
inhibition in MCF10A cells.

With evidence that YPEL3 has growth suppressive properties when expressed in
tumor lines, it is possible that YPEL3 may function as a tumor suppressor gene in vivo.
Additional evidence for this tumor suppressive function stems from the analysis of
YPEL3 mRNA expression levels in human ovarian tumors compared to normal tissue.
Of the tumors sampled, YPEL3 expression levels were consistently lower compared to
normal samples from the same patient (Kelley,K.D., Miller,K.R., et al. 2010). This is an
indication that these tumors may require lower levels of YPEL3 expression to transform
and propagate efficiently. Although this evidence is supportive of the classification of
YPEL3 as a tumor suppressor gene, experiments whereby YPEL3 expression is
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compromised by using either a shRNA based approach in cell lines or by knocking the
gene out in mice are still required. Of these two approaches, clearly the former is less
expensive and labor intensive. Therefore, the ex vivo approach was employed to acquire
preliminary data that would justify investing in YPEL3-knockout mice.
By utilizing virally encoded shRNA targeting the YPEL3 gene, basal expression
of YPEL3 was targeted in transformation-colony formation experiments using MCF10A
cells. The shRNA construct targeting hYPEL3 that is used in the following experiments
has been validated for efficient knockdown (Kelley,K.D., Miller,K.R., et al. 2010).
Although these cells are immortalized to facilitate continuous passaging in culture, they
are not transformed and will normally stop growing when confluency is reached. Thus,
they normally grow to a complete monolayer before stopping cell division. This
monolayer is visualized in three separate images five days after MCF10A cells were
infected with GFP expressing virus at an MOI of 2. Interestingly, compared to GFPinfected cells, MCF10A cells infected with shRNA targeting YPEL3 demonstrate a loss
of contact inhibition as some cells continue to grow above the monolayer (Figure 18,
right panels). They also have a reduced need for growth on the solid surface of culture
plate because these cells, by nature of growing on top of the monolayer, have no
substantial contact with the plate’s surface. This phenotype was transient however. Ten
days after transfection they die off and leave only cellular debris on the monolayer
surface—a phenomenon seen in two independent experiments (Figure 19). In summary,
infection of MCF10A immortalized mammary epithelial cells with a shRNA construct
targeting YPEL3 demonstrated a transient decrease in the contact / growth inhibitory
properties and solid support proliferation requirements of these cells, but this phenotype
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could not be sustained under long term culturing conditions.
Most malignancies are thought to evolve over a period of time into more
anaplastic states by accumulating a series of alterations in key cell cycle regulatory genes.
This is illustrated by Nowell’s clonal tumor evolution hypothesis (see Introduction
section), which emphasizes that the generation of increasingly neoplastic and aggressive
clonal populations progressing towards “full-blown” oncogenic transformation results
from individual clones—under selective pressure, accruing gain or loss of function
mutations in oncogenes or tumor suppressor genes, respectively (Figure 20). Many
model systems exist that attempt to recreate and study this process of tumorigenesis in
tissue culture settings.
The next experiment attempted to recapitulate this scenario in MCF10A cells, by
targeting genes that regulate cell cycle homeostasis such as oncogenic RAS and p53 in
the background of shRNA mediated reduction of YPEL3 gene expression. The question
was thus asked, would simultaneous attenuation of p53 expression with shRNA and
oncogenic RAS overexpression be able to sustain shYPEL3 –dependent colony formation
above the monolayer in MCF10A cells compared to infection of RAS and shp53 alone?
To answer this question, MCF10A cells were virally infected with a triple combination of
oncogenic RAS, shp53, and GFP (Figure 21 two images on the left) or oncogenic RAS,
shp53 and shYPEL3 (Figure 21, two images on right), and grown for two and four
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Figure 18. Reduced expression of YPEL3 decreases contact inhibition properties
and solid support growth requirements of MCF10A immortalized mammary
epithelial cells
MCF10A immortalized mammary epithelial cells normally grow to a complete
monolayer before stopping division. This is evidenced by the three images in the left
panel which show MCF10A cells infected 5 days earlier (MOI = 2). Cells infected with
shRNA targeting YPEL3 (MOI=2) demonstrate a loss of contact inhibition as they
continue to grow above the monolayer. They also have a reduced need for the solid
surface matrix of the culture plate to support further growth. These images are
representatives of results from two independent experiments.
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Figure 19. The loss of contact inhibition afforded by shRNA mediated-reduction
of YPEL3 expression is not maintainable in prolonged culture conditions.
The image on the left is representative the GFP infected control population after 10
days post-infection. The image on the right displays complete loss of all cells with
decreased contact inhibitive phenotype seen in figure 18. Images are representative
of two independent experiments.

72

73

Figure 20. Nowell’s clonal tumor cell evolution hypothesis
The light and dark blue spheres represent cells that have been exposed to a DNA damaging event which results in genetic mutations. Clonal expansion occurs until a
second mutagenic event occurs which genetically alters the cell even further. The
product of these mutations is a phenotype more advantageous for cell growth and
division compared to other clones in the population, allowing for positive selection of
these clones. Finally after several genomic insults the pre-neoplastic cell eventually
acquires enough mutations that affect the regulation or expression of key tumor
suppressor genes or oncogenes that a cancerous cell arises.
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weeks. Even after 10 days post-infection, cells infected with shYPEL3 (compared to
GFP) showed significant colony formation above the confluent monolayer. This pretransformed phenotype was indeed sustainable beyond 10 days in contrast to infection
with shYPEL3 alone in Figures 18 and 19. This experiment was performed twice over
six weeks. One set of plates was stopped at two weeks and the other set of plates was
stopped at four weeks of growth. In each case cells were stained with crystal
violet/methanol stain to visualize colony formation and revealed significantly more cell
density on plates treated with shYPEL3, RAS and shp53 compared to RAS and shp53
and control GFP virus at both time points (Figure 22). Additional representative images
of controls plates are also included to show that infecting cells with RAS or shp53 alone
did not generate the same phenotype (see Figure 22). Data generated from this
experiment demonstrated that the reduction of YPEL3 expression by shRNA under
conditions leading to the overexpression of oncogenic RAS and reduction of p53
expression, were more advantageous to perpetuating a sustained phenotype where
MCF10A cells lost contact inhibition and solid matrix requirements, than that observed in
Figures 18 and 19 observed with only reduction of YPEL3 expression. Although these
data are very preliminary, these results are very encouraging and lay the foundation for
future transformation experiments both ex vivo—performing soft agar / colony formation
assays and in vivo— utilizing YPEL3 knockout mice to study the effect loss of YPEL3
has on tumor formation.
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Figure 21. Reduced YPEL3 expression along with both oncogenic RAS
overexpression and reduction of endogenous p53 are sufficient to maintain a
transformed phenotype in MCF10A immortalized mammary epithelial cells.
The left panel shows two representative images from plates of MCF10A cells infected
with lenti6-oncogenic RAS, lenti4-shp53, and lenti6-GFP 10 days post-induction.
The right panel shows cells 10 days after infection with the same viral expression
vectors (MOI=2) with the exception that lenti-GFP is replaced with lenti-shYPEL3.
All images are representative of two separate experiments.
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Figure 22. Reduction of YPEL3 gene expression in the presence of oncogenic RAS
and reduced p53 results in increased colony formation in MCF10A immortalized
mammary epithelial cells.
Two and four weeks after infection with respective viral constructs with an MOI of 2,
MCF10A cells were stained with crystal violet to demonstrate the degree of colony
formation above the monolayer. Top panel: (above dotted line) Two weeks after infection
cells were stained with crystal violet and photographed together. Pairs of wells with
black boxes around them are replicates and each pair was infected with the same viral
constructs. Bottom panel: (below dotted line) The left plate was infected with RAS,
shp53 and GFP. The one of the right was infected with RAS, shp53 and shYPEL3. Cells
were allowed to grow for 4 weeks (media changed every 3 days) and then stained with
crystal violet and photographed together.
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Prediction of a theoretical three-dimensional structure of the YPEL3 protein.

Since its completion in 2003, the human genome project has generated an
immense amount of information characterizing the 23,299 protein-coding genes now
annotated according to the Ensembl Gene Repository—a list that does not even include
all gene variants derived from alternative splicing and ORFs. This information is of little
use, however to furthering basic scientific and biomedical research without structural /
functional data regarding the protein products of these genes.
Characterization of a protein’s structure may provide hints to its function.
Therefore, an attempt was made to computationally solve the protein structure of YPEL3
from its primary amino acid sequence using two freely available structure prediction
programs—Rosetta Ab Initio (Das,R. and Baker,D. 2008, Simons,K.T., Bonneau,R., et al.
1999) (Figure 23) and I-TASSER Fold Recognition Server (Zhang,Y. 2008, Zhang,Y.
2009) (Figure 24).
Rosetta ab initio is a protein structure prediction program available for download at
http://www.rosettacommons.org/, and is freely available for academic use. The Rosetta ab
initio structure prediction process relies heavily on C.B. Anfinsen’s seminal hypothesis
that all proteins structures fold toward their lowest energetic state (Anfinsen,C.B. 1973).
Applying this conjecture to the structural prediction of a hypothetical 100 amino acid
protein, if it were possible to assess every possible structure for this protein, with each
amino acid having on average, six degrees of freedom—the average representation of the
true structure would simply be the structure(s) at energetic equilibrium or those that
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Figure 23. The Rosetta ab initio protein structure prediction method
The Rosetta ab initio protein folding method relies on the fact that proteins tend to fold
into stable structures that decrease their thermodynamic free energy state (A and B). The
driving force for this is the burial of hydrophobic side chains (gray spheres) into the
center of the structure along with the exclusion of water molecules from this region as
shown by the folding of this “centroid” model where side chains are accounted for
energetically as single spheres with discrete hydrophobic and electrostatic characteristics.
The Rosetta algorithm uses Monte Carlo-based simulated annealing to computationally
generate several thousand structural predictions. (C) To select the best cluster of
structures that is likely to resemble the true structure, the calculated energies of all
predictions (Appendix, Table 1) are ranked and the group with the lowest energy score is
selected. This process is refined further by using an “all atom” energy algorithms
(Appendix, Table 2) to minimize proposed structures toward the global energy minimum.
Adapted from: DAS R., Baker D. (2008). Macromolecular modeling with Rosetta. Annu
Rev Biochem 77: 363-382.
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Simulated Annealing to all atom refinement based on lowest energy
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Figure 24. The I-TASSER fold recognition server
I-TASSER is a fold recognition and threading server that identifies primary sequence and
secondary structure homologies between the query protein and protein data bank (PDB)
structures. By following this protocol, primary and secondary structural information
derived from the query protein’s amino acid sequence can be used to generate
homologous matches to regions by overlaying or “threading” solved structural regions of
proteins from the Protein Data Bank over the query sequence.
Taken from: Zhang Y. (2009). I-TASSER: Fully automated protein structure prediction in
CASP8 Proteins 77 Suppl: 100-113.; Zhang Y. (2008). I-TASSER server for protein 3D
structure prediction. BMC Bioinformatics 9: 40.
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occupy the lowest possible free energy or “global energy minima.” A protein such as
the one described above would have 6^100 degrees of freedom, therefore, one obvious
problem with structure prediction based solely on total energy calculations is that
sampling all possible conformations that could occupy three-dimensional space is
currently impossible even for relatively small proteins such as this one. It is possible,
however, to computationally sample through enough conformational space to arrive at an
estimate that is reasonably close to the native structure. To extend this logic further, the
probability of arriving at a correct approximation of the native structure will increase
proportionally to the amount of sampling performed (Das,R. and Baker,D. 2008). A
tremendous amount of computational resources are necessary to achieve even low
resolution accuracy and also avoid common pitfalls such as getting “stuck” in a local
energy minimum (Das,R. and Baker,D. 2008). This commonly occurs from insufficient
sampling and results in the generation of incorrect structural predictions that do not truly
occupy the global energy minima but rather represent one of the many local minima that
riddle the energy landscape. With computational resources being limited, the accuracy
of estimating a three-dimensional structure using ab initio –based calculations is
primarily dependent on the number of sample structures generated (decoys). This
calculation is further impacted by a protein’s size being exponentially proportional to the
number of structural confirmations possible (Das,R. and Baker,D. 2008, Simons,K.T.,
Bonneau,R., et al. 1999).
Based on the above reasoning, success using Rosetta has only been achieved
solving relatively small proteins around 100 amino acids in size. These predictions have
been superimposed over native structures solved by X-ray crystallography to within 2-4
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angstroms RMSD (Simons,K.T., Bonneau,R., et al. 1999). These low resolution
structures have been predicted by generating ensembles containing only a few thousand
decoys and then choosing the cluster with the most neighbors and lowest energy using
protocols similar to that used to predict YPEL3, briefly detailed next.
A Rosetta fragment library generator script along with the 119 amino acid YPEL3
sequence as input was employed to generate fragments libraries containing either 3 or 9
amino acid length fragments corresponding to parts of the YPEL3 primary sequence from
parts of known structures with similar stretches of sequence derived from the RCSB
Protein Data Bank. These fragments libraries are assembled into potential structures
termed decoys by a Monte Carlo based-annealing approach along with energy
minimization perturbation protocols. During this procedure, minimization involves using
an energy score 12 to assess local chain perturbations or “moves” in each tertiary structure
generated during the decoy generation and then accept or reject them based on
Metropolis-based probability. In other words, if the local energy score improves—the
move is accepted. If the “move” results in a higher (worse) energy score, this move is
either accepted or rejected based on the degree to which the energy at a given simulation
temperature is unfavorable (based on Boltzmann factor probability). For prediction of
YPEL3, a total of 50,000 decoys were generated over a period of 2 months using two
computers running four processors each at 100% capacity. From these, the decoys were
ranked based on Rosetta energy score and the top 5,000 structures were clustered. From
the top 100 clusters (groups of decoys having structural similarity to each other), 10
12

An arbitrary thermodynamic estimation of the degree of effective hydrophobic burial of nonpolar side
chains as well as the energy cost of polar side chain burial and hydrogen bond formation to compensate for
this cost. Solvation and long range electrostatic interactions are ignored which likely contribute to the high
error (~10%) inherent with complex energy calculations.
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representative centroid models from the best 10 clusters were selected for further
analysis.
The second approach used to model YPEL3’s 3D structure was to submit the amino
acid sequence for YPEL3 to the I-TASSER (Threading ASSEmbly Refinement)
homology-based fold recognition server (Zhang,Y. 2008, Zhang,Y. 2009). This is fully
automated server only requires the user deposit the amino acid sequence of the protein of
interest along with an e-mail address to return results to. The server can be found at:
http://zhanglab.ccmb.med.umich.edu/I-TASSER/. The program begins by searching both
primary and calculated secondary structures against the PDB library to find matches with
>70% pair-wise similarity. The program then “threads” the query sequence over
matching folds from the database and the 3D coordinates of these folds are then exported
and recombined to assemble a potential structure for the query sequence (Zhang,Y. 2008,
Zhang,Y. 2009). To refine this prediction further, energy minimization is then performed
using a similar, though less exhaustive simulated annealing method used also in Rosetta
ab initio, to model coordinates of connecting protein loops more precisely.
The top 5 best structural predictions of YPEL3 were returned along with a predicted
secondary structure and a structural alignment of the best 10 matches of the predicted
YPEL3 structure with experimentally solved structures from the protein data bank
(Figure 25). These results will be discussed in the next section.
Resulting structures generated for YPEL3 from each independent method of structural
prediction converge on a similar fold.
After superimposition of the Rosetta ab initioYPEL3 prediction (Figure 26, yellow
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Figure 25. I-TASSER fold recognition server structural prediction results for
YPEL3.
The I-TASSER automated server returned the top five predictions seen in the top panel
below the YPEL3 query sequence which are relatively close in (alpha carbon trace)
structure to each other with the exception of secondary structure characteristics.
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structure) with the I-TASSER YPEL3 prediction using UCSF Chimera Matchmaker
(Pettersen,E.F., Goddard,T.D., et al. 2004) (Figure 26, purple structure), an alignment of
35 atom pairs within a root mean square deviation (RMSD) of 3.9Å was evident when
comparing both structures to each other; this similarity between structures is apparent by
visual inspection especially surrounding the two pairs of cysteines on separate loops that
fold to establish a metal coordination motif in both Rosetta ab initio and I-TASSER
predictions (Figure 26, bottom panel). Even more intriguing is the fact that an
automated server called the ROBETTA Protein Prediction Server (Figure 27, white
structure), which relies on the same code and energy calculations as Rosetta ab initio,
generated a structure that aligned with the I-TASSER prediction (Figure 27, purple
structure) even more precisely than comparisons observed between the Rosetta ab initio
structure and I-TASSER prediction (see figure 26). This may be due to the fact that
Robetta performs an additional step to search for structural homology to the query
sequence using PSI-BLAST and the Pfam database before generated 10K decoys and
selected the lowest energy cluster.
The predicted YPEL3 structure is structurally homologous with an enzyme involved in
the oxidative stress response.
A search for solved protein structures with similarity to the YPEL3 predictions
was performed next. This search consistently returned homology matches with the zinc
finger containing protein: Methionine-R-sulfoxide reductase from several prokaryotic
species including Burkholderia pseudomallei (Figure 28), Methanothermobacter
thermautotrophicus and Neisseria gonorrhea (see figure 25, bottom panel). For example,
superimposition between Methionine-R-sulfoxide reductase from Burkholderia
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Figure 26. The Ab initio Rosetta and I-TASSER prediction models for YPEL3
overlap within 3.5 Å for 35 /119 amino acids.
The Ab initio Rosetta-predicted structure (yellow) was manually determined in eight
weeks using two computers each containing a quad core processor. Fifty-thousand
decoys were produced and sorted to give only the top 5000 best predictions based on
Rosetta energy calculations for each structure. These structures were then clustered by
structural similarity and the top 10 clusters with the most members and lowest energy
were selected for further analysis. After further minimization and idealization of bond
lengths and torsion angels, the structure in yellow was generated (top, left structure). The
I-TASSER prediction model in purple (top, right structure) was far less labor intensive to
generate and much less computationally. Bottom panel: Both structures were
superimposed using University of California San Francisco's Chimera MatchMaker
algorithm. They overlapped with each other within 3.5 Å for 35 /119 amino acids.
Although this is only around 1/3 of the total protein it is important to point out that key
structural motifs such as that the loops containing cysteines (highlighted in green) that
make up a putative zinc finger motif align with a high degree of overlap in both
molecules.
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Figure 27. YPEL3 structures calculated with I-TASSER and the ROBETTA server
align with a high degree of overlap.
ROBETTA—the fully automated online version of the stand alone Rosetta code used to
generate the structure in the previous figure, was used to predict YPEL3’s structure. At
the time of this work, there was a significantly long wait for ab initio structure prediction
resources when trying to use ROBETTA. This led to the YPEL3 structural prediction
request sitting in queue for 6 months before being processed. The prediction (white
structure on the left) that was returned by ROBETTA however showed significant overlap
with the I-TASSER prediction (purple structure on the right). The RMSD between
structures was 2.9 Å for 70 amino acid pairs determined from UCSF Chimera
MatchMaker (bottom overlay).
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Figure 28. The predicted YPEL3 structure is structurally homologous with an
enzyme involved in the oxidative stress response.
Top panel: protein data bank repository crystal structure screen shot and structural
characteristics of 3CEZ or Methionine-R-sulfoxide reductase. Bottom Panel: two images
of the superimposition between 3CEZ (orange structure) and the I-TASSER YPEL3
prediction (purple structure).
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Figure 29. Structural homology between the I-TASSER predicted structure of
YPEL3 and the crystal structure of Methionine-R-sulfoxide reductase.
The Methionine-R-sulfoxide reductase crystal structure (3CEZ) is shown in blue (top,
left) and the I-TASSER YPEL3 prediction is shown in purple (top, right)
Superimposition of both structures reveals an RMSD of 3.2 Å between 78 (alpha carbon)
atom pairs.
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Figure 30. Structural homology between the Rosetta ab initio YPEL3 prediction
and Methionine-R-sulfoxide reductase crystal structure
The Rosetta ab initio structure (top, left) in yellow and Methionine-R-sulfoxide reductase
crystal structure (top, right) in blue were superimposed in the bottom panel with Chimera
MatchMaker with a RMSD of 4.1 Å between 34 amino acid pairs. Cysteines that
compose the putative zinc finger motif are shown and highlighted in green.
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pseudomallei with the YPEL3 structural prediction from either I-TASSER (Figure 29) or
Rosetta ab initio (Figure 30), revealed an alignment of 78 atom pairs with 3.2Å RMSD
and 34 atom pairs at 4.1Å RMSD, respectively.
Methionine-R-sulfoxide reductase is involved in the oxidative stress response and
functions to compensate for redox damage to proteins by reducing oxidized methionine
(Etienne,F., Spector,D., et al. 2003). There is also evidence that these enzymes may not
just repair methionine residues but act to process and eliminate cellular reactive oxygen
species (ROS) pools by proxy through reducing susceptible methionines on affected
proteins throughout the cell (Etienne,F., Spector,D., et al. 2003, Levine,R.L., Berlett,B.S.,
et al. 1999, Levine,R.L., Moskovitz,J., et al. 2000). In other words, the availability of
exposed methionines on the surface of cellular proteins makes up a large pool of reactants
that could scavenge significant amounts of ROS. The resulting product, methionine
sulfoxide could then be reduced back to its native state by these reductases, and again be
ready to accept more ROS if necessary. Although enzymes that reduce methionine
sulfoxide in mammalian cells have already been characterized, there may be more than
one type enzyme that can accomplish this process and also establish redundancy for such
an important process as the oxidative stress response. This could implicate YPEL3 and
its family members in mammalian cellular antioxidant processing and signaling;
especially considering that YPEL3 is transcriptionally regulated by oxidative stress
responsive genes such as p53. Indeed, YPEL3’s role in mediating premature cellular
senescence may also have some connection to upstream signaling, sensing or processing
of oxidative damage by YPEL3 downstream of p53 transactivation. Further because
aging and the oxidative stress response are viewed as closely connect processes there is
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incentive to investigate YPEL3’s role in aging.
In summary, a model for the protein of structure of YPEL3 was generated by
employing two independent structural prediction processes, the I-TASSER fold
recognition program and Rosetta ab initio algorithm to generate two similar protein folds
(Figure 31). The most exciting aspect of the two predicted models is that they both
converge on a similar structure even though each of the two prediction techniques relied
on a different mechanism to solve YPEL3’s structure. Furthermore, supporting that the
process of manually solving YPEL3’s structure using Rosetta ab initio was done correctly
and strengthening the probability of calculating a model similar to the native structure of
YPEL3 is the fact that a third prediction program, ROBETTA—an automated version of
Rosetta ab initio arrived at a similar prediction. Moreover, this prediction aligns with the
I-TASSER prediction with an even greater degree of precision than the Rosetta ab initio
model. Lastly, three-dimensional blast searches against known crystal structures within
the PDB revealed homology between the computed YPEL3 model and a protein involved
in physiological response to oxidative stress. This implication along with YPEL3’s
involvement in the regulation of senescence downstream of p53 (Kelley,K.D.,
Miller,K.R., et al. 2010) may reveal more about the mechanism of how YPEL3 functions
to induce cellular senescence.

103

Figure 31. Summary of YPEL3 structure prediction using two separate
computational prediction methods.
Two relatively independent prediction algorithms, Rosetta ab initio and the I-TASSER
fold recognition server were used to predict the three-dimensional structure for the
YPEL3 protein. Each prediction converged toward a similar structure as the other. This
structure has homology to the crystal structures of a family of prokaryotic
oxidoreductases—the Methionine-R-sulfoxide reductases which are involved in the
intracellular oxidative stress response.
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PART II

FHIT is regulated through the AKT/ PI3K/FOXO3a pathway
in response to mitogen depletion.
INTRODUCTION TO PART II

The FHIT Tumor Suppressor Gene

Fragile Histidine Triad, FHIT, is a 1.7 MB gene encoding a 16.8-kDa protein
(Gatalica,Z., Lele,S.M., et al. 2000). First identified in digestive tract cancers, FHIT gene
expression was absent apparently as a result of deletions in the coding region of the gene
(Ohta,M., Inoue,H., et al. 1999)(Smith,D.I., McAvoy,S., et al. 2007). This finding
provided the first clue that FHIT may have a tumor suppressive function. It was
subsequently determined that the location of the FHIT gene, 3p14.2, was located over one
of the most common human fragile sites, the FRA3B locus (Ohta,M., Inoue,H., et al.
1996). Analysis of human lung cancer samples hinted at links between smoking, loss of
FHIT expression, and lung tumor formation (Yanagisawa,K., Kondo,M., et al. 1996). It
was later discovered that the human FHIT gene was susceptible to mutation and loss of
function from exposure to mutagens and carcinogenic compounds present in tobacco
products (D'Agostini,F., Izzotti,A., et al. 2006, Pang,Y., Li,W., et al. 2008)(Pichiorri,F.,
Palumbo,T., et al. 2008, Smith,D.I., McAvoy,S., et al. 2007). Double strand breakage is
thought to occur at the FRA3B locus as a result of carcinogen exposure or late and
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incomplete DNA replication at this site; breakage results in either complete loss of FHIT
gene expression or reduction to levels which are not sufficient to maintain tumor
suppressive function (Huebner,K. and Croce,C.M. 2001).
Aberrant FRA3B loci can be visualized by cytogenetic analysis of karyotypes
isolated from many FHIT-null tumor samples which typically reveal chromosomal
deletions or translocations involving these regions (Huebner,K. and Croce,C.M. 2001).
Loss of FHIT expression by these mechanisms can result from chronic carcinogen
exposure and has been shown to be one of the earliest events in lung cancer
carcinogenesis (Herbst,R.S., Heymach,J.V., et al. 2008). As such, diagnostic monitoring
of FHIT expression levels in sputum samples has been proposed as a method for high
throughput detection of early stage lung carcinoma (Li,R., Todd,N.W., et al. 2007).
The complete mechanism detailing how FHIT functions as a tumor suppressor has
been unknown since the gene’s discovery over a decade ago. It is currently know that
FHIT functions enzymatically as a diadenosine triphosphate hydrolase; however, this
activity was shown not to be necessary for onco-suppression (Campiglio,M., Bianchi,F.,
et al. 2006). In spite of this finding, enzymatic substrate binding was found to still be
required for tumor suppression by FHIT. This has been verified by experiments testing
hydrolase and diadenosine triphosphate binding mutants for tumor suppressive function.
The requirement for dinucleotide triphosphate binding may indicate that FHIT functions
in signaling cascades similar to large heteromeric G-proteins which also bind nucleotide
triphosphates upon activation of signaling (Trapasso,F., Krakowiak,A., et al. 2003). It
has also been demonstrated that FHIT is involved in the regulation of death receptor
signaling (Deng,W.G., Nishizaki,M., et al. 2007). FHIT has also been linked to
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activation of intrinsic (mitochondrial) apoptotic pathways by interaction with Feredoxin
reductase and concomitant generation of reactive oxygen species (ROS) resulting in the
induction of programmed cell death (Trapasso,F., Pichiorri,F., et al. 2008).
In addition to the biological link between FHIT expression and lung carcinogenisis, FHIT
expression levels are reduced in certain types of breast cancer(Bianchi,F., Tagliabue,E., et
al. 2007, Campiglio,M., Pekarsky,Y., et al. 1999, Gatalica,Z., Lele,S.M., et al. 2000,
Guler,G., Uner,A., et al. 2004, Guler,G., Uner,A., et al. 2005, Huiping,C., Jonasson,J.G.,
et al. 2000, Iliopoulos,D., Guler,G., et al. 2005, Ingvarsson,S., Agnarsson,B.A., et al.
1999, Ingvarsson,S., Sigbjornsdottir,B.I., et al. 2001, Tang,X.L., Yao,G.Y., et al. 2006,
Wang,Z.B., Zhao,P., et al. 2006, Yang,Q., Nakamura,M., et al. 2002, Yang,Q.,
Yoshimura,G., et al. 2002, Zochbauer-Muller,S., Fong,K.M., et al. 2001). For instance,
FHIT has recently been shown to protect against HER2-driven breast tumor development.
Loss of heterozygosity at the FHIT locus in breast tumors is associated with decreased
patient survival and increased tumor burden (Bianchi,F., Tagliabue,E., et al. 2007).
Moreover, reduced expression of FHIT has been shown to correlate with the expression
of other fragile site-susceptible tumor suppressors such as WWOX in high grade-ductal
carcinoma in situ (DCIS) breast cancers (Bianchi, F., et al, 2007). In summary, FHIT is
an important tumor suppressor gene whose functions are vital to inhibiting epithelial
tumor formation (Figure 32).
Rationale
With the exception that exogenous E2F-1 (Ishii,H., Mimori,K., et al. 2004) can induce
FHIT gene expression, little is known about the transcriptional regulation of
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Figure 32. The FHIT tumor suppressor gene.
FHIT and its role in suppression of tumor development have been extensively studied.
Loss of FHIT occurs through expression of a common fragile site encompassed by the
FHIT locus or through methylation of the FHIT promoter.
Adapted from: Saldivar JC, Shibata H, Huebner K. Pathology and biology associated
with the fragile FHIT gene and gene product. J Cell Biochem. 2010 Apr 1;109(5):858-65.

109

Current literature supporting FHIT as an important tumor suppressor gene

Adapted from: J Cell Biochem. 2010 Apr 1;109(5):858-65. Pathology and biology associated with the
fragile FHIT gene and gene product. Saldivar JC, Shibata H, Huebner K.
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FHIT. That is not to say that transcriptional regulation doesn’t play an important role in
the loss of FHIT tumor suppressive function. For example, there is evidence that
epigenetic mechanisms of transcriptional silencing such as FHIT promoter
hypermethylation contribute to the loss of FHIT expression and tumor progression
(Goldberg,M., Rummelt,C., et al. 2006, Iliopoulos,D., Guler,G., et al. 2005, Wali,A.,
Srinivasan,R., et al. 2006, Yang,Q., Nakamura,M., et al. 2002, Zochbauer-Muller,S.,
Fong,K.M., et al. 2001). Surveys of FHIT expression in breast cancer tissue have
revealed that 60-70% of tumor samples had strikingly reduced or no FHIT protein, and of
these, only 30-35% contained aberrant transcripts resulting from purely genetic
alterations (Bianchi,F., Tagliabue,E., et al. 2007). Thus, the discrepancy between FHIT
protein and aberrant transcript production is evidence for other causes of FHIT loss
besides fragile site expression alone. Further, the remaining breast tumors analyzed from
the above study contained full length FHIT mRNA but at reduced levels compared to
normal tissue, thus providing additional support for the existence of transcriptional modes
of regulation of FHIT gene expression and emphasizing the importance of understanding
how FHIT is regulated at the transcriptional level. Lastly, little is known about how
FHIT gene expression is regulated in dividing cells
FHIT gene expression is upregulated after p53 activation by siRNA targeting HdmX
and Hdm2.
Revisiting microarray experiments performed to screen for new p53 target genes
demonstrated that FHIT expression was elevated in MCF7 cells treated with siRNA
targeting HdmX and Hdm2. This observation was confirmed by qPCR (Figure 33).
However, there was no decrease in FHIT mRNA levels as a result of lowering p53
expression which is an indication that FHIT was most likely not a direct target of p53.
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Figure 33. RNAi targeting HdmX or Hdm2 leads to an increase in FHIT mRNA.
MCF7 cells were transfected with siRNAs targeting the indicated genes or a nontargeting control (siCon). Total RNA was isolated 24 hours after transfection and p21 and
FHIT mRNA levels were quantified by RT-PCR. The y-axis represents the relative
quantity (RQ) of mRNA normalized to GAPDH mRNA levels.
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However, treatment with both siHdmX and sip53 did not result in an
increase in FHIT expression seen with siHdmX alone. This is an indication that the
elevation of FHIT mRNA in response to siRNA-mediated HdmX depletion could be
indirectly dependent on p53. Considering these results, the next step was to determine if
FHIT gene expression could be induced by p53 overexpression and DNA damage
experiments. The rationale for doing so can be found in the introductory section of this
document regarding p53.
FHIT is not a direct target of p53
To further investigate whether FHIT was a direct target of p53, transient
transfection of p53 into MCF7 cells was performed, but no increase in FHIT mRNA was
observed 24 hours post-transfection (data not shown). While interpreting this negative
result, it was considered that post-translational modifications of p53 such as DNA
damage dependent-phosphorylation (Riley,T., Sontag,E., et al. 2008) may be necessary to
trigger p53 transactivation of FHIT gene expression. To test this, MCF7 cells were treated
with a series of different DNA damaging agents to activate p53 through different DNA
damage response pathways. For example, Bleomycin was used because it can cause
DNA double strand breakage similar to ionizing radiation and signals primarily through
the ATM kinase damage response pathway to activate p53(Chen,J., Ghorai,M.K., et al.
2008, Jazayeri,A., Falck,J., et al. 2006, Sun,Y., Xu,Y., et al. 2007). On the other hand, 5fluorouracil (5-FU) binds and inhibits thymidylate synthase, and by doing so lowers
thymine nucleotide reserves and inhibits DNA synthesis (Noordhuis,P., Holwerda,U., et
al. 2004). In addition, 5-FU can also activate p53 downstream of ribosomal stress
(Sun,X.X., Dai,M.S., et al. 2007).
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Figure 34. FHIT mRNA levels increase in response to bleomycin but not
doxorubicin or 5-fluorouracil treatment.
76Ntert cells were treated with increasing doses of the radiomimetic bleomycin for 24h
followed by RT-PCR analysis of FHIT, p21 and BAX treatment (left panel). MCF7 cells
were treated with 0.5µg/ml of doxorubicin for 24h and then p21 and FHIT mRNA levels
were determined (top, right panel). 76nTert immortalized mammary epithelial cells were
treated with 1µg / ml of 5-fluorouracil for 24h followed by assessing p21 and FHIT
mRNA levels (bottom, right panel). All gene expression levels are normalized against
their respective mock-treated control. Error bars represent the 95% CI of three technical
replicates.
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Figure 35. RNAi targeting Mdm2, MdmX and p53 is able to modulate PG13-luc
luciferase activity.
The PG13-luc luciferase reporter was used as control to measure changes in intracellular
p53 activity. The promoter of this reporter contains a series of thirteen p53 consensus
binding sites (top panel). MCF7 cells were transfected with siRNA for three consecutive
days. Twenty-four hours following siRNA transfection, cells were cotransfected with
PG13-luc and Renilla-luc (Bottom panel). Twenty-four hours post-transfection, whole
cell lysates were assessed for luciferase activity. Each sample was read in technical
duplicates and assessed by student t –test. Asterisks represent p<0.05.

117

118

Figure 36. The 5´ FHIT promoter-luc does not demonstrate increased luciferase
activity in response to RNAi targeting Mdm2, Mdm2 or p53
The 5´ flanking region of the FHIT gene from -800 to +146, was cloned into the PGL3Basic luciferase reporter vector (top panel). MCF7 cells were transfected with siRNA
targeting the indicated genes (x-axis) and after 24h subsequently cotransfected with FHIT
promoter-luc and Renilla-luc. Twenty-four hours post-transfection whole cell lysates
were assessed for luciferase activity. The error bars represent standard deviation of
biological duplicates.
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After treatment of 76nTert and MCF7 cells, no increase in FHIT mRNA was
observed in response to treatment with either 5-FU or doxorubicin (Figure 34, right
panel). Bleomycin treatment however, did result in up to a two-fold induction of FHIT
mRNA (Figure 34, left panel). This result was puzzling, however, because other types of
previously mentioned DNA-damage did not result in such an increase. It was considered
that perhaps this was because only specific types of DNA damage were signaling through
p53 to trigger an induction of FHIT gene expression at least in the case of ATMdependent signaling—resulting from double strand breaks caused by bleomycin but not
from DNA damage caused by doxorubicin intercalation or 5-FU-induced ribosomal
stress. To determine whether or not the FHIT promoter contained a functional p53
response element that may be responsible for increases in FHIT gene expression in
response to DNA-double strand breakage, two regions of the FHIT promoter were cloned
into the PGL3-BASIC luciferase reporter vector and tested in the presence of siRNAdependent reduction of HdmX and Hdm2 (Figure 35 and 36), and, p53, p63γ and p73α
overexpression (Figure 38) or in the presence of p53 alone (Figure 37). Each reporter
contained at least 900 base pairs either upstream (5'-FHIT-luc) or downstream (3'-FHITluc) of the FHIT transcription start site. These regions were chosen because together they
included two potential p53 binding motifs above a 60% threshold of similarity to the p53
consensus binding site (data not shown). None of the above treatments resulted in
stimulation of either of the two FHIT luciferase reporters. From these negative results
generated from assessing the potential for p53 transactivation of the FHIT promoter, it
was concluded that a role for p53 in regulating FHIT gene expression could not be
validated.
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FHIT gene expression is cell cycle dependent.

After examining p53 as a possible trans-acting factor responsible for
regulation of FHIT gene expression downstream of attenuation of Hdm2/X, other
transcription factors were considered. For example, exogenous E2F-1 was already
known to bind to and activate transcription of FHIT (Ishii,H., Mimori,K., et al.
2004). It has been reported that E2F-1 is negatively regulated by HdmX (Strachan,G.D.,
Jordan-Sciutto,K.L., et al. 2003, Wunderlich,M. and Berberich,S.J. 2002, Wunderlich,M.,
Ghosh,M., et al. 2004). Therefore, cell synchronization experiments were conducted to
determine if FHIT expression modulated in cell cycle specific patterns which could
suggest a mode for E2F regulation. Either aphidocolin (Figure 39) or nocodazole (Figure
40) were used to synchronize MCF7 cells at the G1/S or G2/M phase of the cell cycle,
respectively. In the case of the aphidicolin treatment, once synchronized, cells were
released into complete media and permitted to enter back into the cell cycle. FHIT
expression was monitored for changes in expression by collecting plates of at specific
time points for protein and flow cytometric analysis by PI staining (Figure 39) Cyclin
A2 was used as a positive control for synchronization because its expression is typically
elevated as cells progress from G1 into S phase. It was apparent from Western blotting
that FHIT expression decreased as cells progressed from G1 toward S and G2 phase.
In MCF7 cells treated with nocodazole to arrest cells in G2/M, followed by
release into complete media, FHIT mRNA levels increased as cells left G2/M and entered
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Figure 37. The FHIT 5´ promoter does not contain any response elements to p53,
p63γ, or p73α.
The 5´FHIT- luc (top panel) was cotransfected into MCF7 cells with Renilla-luc and
either p53, p63γ, or p73α expression vectors. Extracts were assessed for luciferase
activity 24h later and biological duplicates for each condition were averaged with error
bars representing standard deviation (Bottom panel).
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Figure 38. Exon 1 and the 5´ region of intron 1 do not contain any responsive p53
binding sites.
A 1100 bp region further three prime of the sequence contained in the 5´FHIT-luc
reporter was cloned into pGL3-Basic. This reporter contained the first ~200 bp of the
promoter region, exon 1 and part of intron 1 and is termed 3´FHIT-luc (top panel).
MCF7 cells were cotransfected with Renilla-luc and either empty vector (PGL3-Basic),
3´FHIT-luc, or 3´FHIT-luc + p53. Twenty-four hours post-transfection cells were lysed
and extracts were assayed for luciferase activity relative to Renilla-luc activity to control
for transfection efficiency (bottom panel). Error bars represent standard error of the
mean of biological duplicates.
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Figure 39. FHIT protein expression decreases as MCF7 cells traverse the G1 / S
phase boundary.
MCF7 cells were synchronized at the G1 / S phase boundary by serum deprivation for
24h followed by treatment with complete media containing 1 µg / ml aphidicolin to
temporarily block DNA polymerase. Following a 24h incubation, cells were rinsed 3X
in PBS and released into complete media. Cells were collected and assayed at the
indicated times and assessed by flow cytometry (top panel) or western blot (bottom
panel) for FHIT protein levels as cells progress out of G1. Also, cyclin A protein stability
with respect to cell cycle is illustrated.
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Figure 40. FHIT mRNA expression increases as cells progress from G2/M back into
the G1 phase of the cell cycle.
MCF7 cells plated in T75 flasks were serum starved for 24 hours followed by release into
complete media containing 4µM nocodazole for 16 hours. Cells were rinsed 3X in PBS
followed by release into complete media. Flasks were vigorously vortexed horizontally
for 30 seconds to release mitotic cells into media. These cells were spun down in falcon
tubes and stored on ice. Using recycled media, this process was repeated 10 times, every
5 minutes. Synchronized cells were re-plated on 6cm plates in complete media. Cells
were harvested every three hours for 18 h. FHIT, cyclin A2, and cyclin D1 transcript
levels were analyzed by RT-PCR (top panel). Propidium Iodide staining and flow
cytometry was performed on cells isolated at each time point to examine cell cycle
distribution after nocodazole release (bottom panel).
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into G1 phase. Cyclin A2 mRNA levels went down and cyclin D1 mRNA levels
increased which is typical of synchronized cells entering G1 (Figure 40).
Taken together, data from synchronization experiments releasing cells at
different points in the cell cycle indicated that FHIT levels were highest when cells were
in the G1 phase of the cell cycle compared to all other phases. Furthermore, upregulation
of FHIT mRNA and protein levels was verified after prolonged deprivation of serum and
subsequent G1 arrest of MCF7 cells during synchronization protocols (see Figure 42).
This finding was intriguing because it suggested a common mechanism for the
modulation of FHIT expression. It was hypothesized from these data that FHIT levels
may be regulated based on position in the cell cycle. In support of this, serum
deprivation treatment and p53 activation after reduction of Hdm2/X expression
(Heminger,K., Markey,M., et al. 2009) both result in cells arresting in G1. Each of these
treatments also leads to an increase in FHIT gene expression. Further, an elevation in
FHIT expression as cells entered and progressed through G1 was observed from
synchronization experiments (see Figures 39 and 40).
The pattern of FHIT expression in synchronized cells progressing through G1
and into S phase of the cell cycle could be E2F-dependent based on reports of a
functional E2F binding site in the promoter (Ishii,H., Mimori,K., et al. 2004). However,
upregulation of FHIT expression in serum starved cells argued against such a regulatory
role because this treatment results in cells entering a quiescent state during which E2F is
normally repressed by hypo-phosphorylated Rb (van den Heuvel,S. and Dyson,N.J.
2008). Furthermore, although the inhibitory effect of HdmX on FHIT expression (see
Figure 33) could be explained through E2F also being released from HdmX repression
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(Strachan,G.D., Jordan-Sciutto,K.L., et al. 2003, Wunderlich,M., Ghosh,M., et al. 2004)
and subsequently driving transcription of FHIT, the same cannot be stated for the effects
on FHIT expression seen in response to treatment with siRNA targeting Hdm2. This is
because Hdm2 leads to stabilization of E2F-1 by blocking its interaction with the E3
ligase—Skp2 (Zhang,Z., Wang,H., et al. 2005). This positive regulatory relationship
would argue against E2F activation in response to siRNA mediated repression of Hdm2.
However, to complicate matters even further, due to the high degree of homology
between E2F family members’ consensus binding sites (Xu,X., Bieda,M., et al. 2007), it
is possible that different E2F family members could bind to the same binding sequence
and either repress (i.e. E2F-4-8) or activate transcription at this promoter region (i.e.
E2F-1-3)(Balciunaite,E., Spektor,A., et al. 2005, Conboy,C.M., Spyrou,C., et al. 2007).
Thus it was possible that E2F-4-8 could have been involved in the repression of FHIT
transcription during G2/M and S phase—when they are themselves not inhibited by
p130/p107 pocket protein binding during G1 and thus would not be able to inhibit FHIT
transcription (Balciunaite,E., Spektor,A., et al. 2005). To alleviate these discrepancies,
and determine if E2F factors play any role in the regulation of FHIT gene expression
during the cell cycle, reporter analysis of the FHIT promoter containing an
experimentally determined E2F binding site (Ishii,H., Mimori,K., et al. 2004) was carried
out.
The cell cycle dependency of FHIT gene expression does not involve E2F.
A luciferase reporter containing the 5´ FHIT promoter region encompassing a
verified E2F consensus binding site (Ishii,H., Mimori,K., et al. 2004) was cloned to test
for potential involvement of E2F in the regulation of cell cycle-dependent FHIT gene
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expression. To ensure that the reporter contained a functional E2F binding site,
cotransfection of both the FHIT-luc reporter and E2F-1/DP-1 plasmids was
performed and resulted in a two-fold increase in relative luminescence compared to
cotransfection with a CMV vector control (Figure 41). Moreover, a site-directed mutant
reporter that contained a mutation in the E2F binding site abrogated this increase in
luciferase activity in response to exogenous E2F-1/DP-1. Following this validation, the
construct was tested to determine if the presence of the E2F binding site would affect
FHIT promoter activity in cycling cells by transfecting MCF-7 cells and subsequently
serum depriving them (data not shown) or synchronizing them and performing a time
course analysis. Both conditions failed to stimulate an increase in FHIT-luc reporter
luciferase activity. This reporter was also previously tested in the presence of the same
combinations of siRNA targeting Hdm2, HdmX and p53 used in the original microarray
screening, however no difference in luciferase activity was seen when comparing
siControl treated cells to those treated with siHdm2, siHdmX or sip53 (see Figure 36).
It was concluded from the above data that E2F was not responsible for the elevation of
FHIT gene expression seen in response to siRNA targeting Hdm2/X, serum deprivation
or synchronization.
Determining how FHIT gene expression is negatively regulated by growth factor
receptor signaling.

Considering the elevation of FHIT levels seen upon mitogen removal and
subsequent G1 arrest (Figures 42-44), it is known that activation of p53 through
siRNA-mediated reduction of HdmX and Hdm2 activity also triggered a similar
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Figure 41. The consensus E2F binding site contained in the FHIT promoter is not
required for modulation of FHIT expression during cell cycle progression.
(A) The CMV-luc reporter, expressing the fire fly luciferase gene under the control of
CMV promoter (left graph), 5´ FHIT-luc containing a E2F consensus binding site
(center graph), or the 5 ´ FHIT-luc reporter containing a site-directed mutant E2F
binding site were each cotransfected with either empty vector (CMV) or a combination
of E2F-1 and DP-1. Luciferase expression was assayed 24 hours after transfection. (B)
The E2F binding site is present in the wild type FHIT promoter contained in wildtype
5´FHIT - luc. Nucleotides changed by site directed mutagenesis to inhibit E2F binding to
ΔE2F 5´ FHIT-luc are shown in red. (C) FHIT 5´-luc or CMV-luc was transfected into
MCF7 cells. Following transfection, cells were serum starved for 24h and subsequently
treated with 1 µg / ml aphidicolin for 24 hours. After release into complete media, cells
were harvested at the indicated times and assayed for luciferase expression.
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Figure 42. FHIT expression increases in response to mitogen removal and
subsequent G1 arrest in MCF7 cells.
MCF7 cells were treated with serum containing media (0 h) or serum starved for either
48 or 72 hours. FHIT protein expression was determined by Western blotting (top panel,
left) and RT-PCR (top panel, right) for each time point. Cells from 0, 48 and 72h
treatments were analyzed by flow cytometry to determine cell cycle distribution (bottom
panel).

136

137

arrest in G1 (Heminger,K., Markey,M., et al. 2009). Taken together with the
observation that FHIT levels modulate as cells move into G1 from cell synchronization
experiments (see Figures 39 and 40), expression of FHIT clearly appears to be regulated
in a cell cycle-dependent manner. It is still not known however, whether the effects seen
on FHIT expression as a result of synchronization, mitogen depletion or siRNAmediated activation of p53 are mediated by different factors or induced through the same
mechanism.
To address the above issue further, a stepwise approach was taken in order to
connect related pieces of data with current literature primarily focused on growth factor
receptor signaling. Data demonstrating that FHIT gene expression was elevated after the
removal of mitogens was chosen as a starting point because this observation could be
linked directly to what is currently known about mediators downstream of the growth
factor receptor / mitogen complex. Following validation of FHIT gene expression
changes in response to serum deprivation, downstream mediators such as AKT and PIP3
kinase were examined to determine if they were also involved in regulating FHIT gene
expression downstream of growth factor stimulation. With the aid of molecular pathway
database analysis tools such as the Ingenuity Pathway Analysis (IPA) program (Ingenuity
Systems, Redwood City, CA), other downstream intermediates were selected for
additional analysis in order to “walk” down the most likely regulatory pathway. For
example, there are numerous factors regulated downstream of AKT/PIP3K which could
be potentially involved in FHIT regulation (Figure 45). By taking into account which
factors are negatively and positively regulated by AKT, and which are transcription
factors and thus likely to affect the expression of another gene such as FHIT, IPA can be
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used to narrow the search for regulatory factors significantly. Also, the biological
function of FHIT, which is primarily growth suppressive, was taken into account when
selecting factors upstream of FHIT that would most likely facilitate a growth suppressive
phenotype. To determine the effect of cellular entry into quiescence on FHIT gene
expression, both normal and tumor cell lines were investigated to ensure that the original
result regarding FHIT expression increasing after serum deprivation of MCF7 cells was
not the result of a genetic deregulation inherent in this particular transformed cell line.
Therefore, immortalized MCF10A mammary epithelial cells were deprived of mitogens
and FHIT protein and mRNA levels were both observed to increase (Figure 44). HCT116
colon carcinoma cells also showed a similar increase in FHIT expression downstream of
serum removal (Figure 43). In conclusion, FHIT expression increases seen downstream
of mitogen removal were not cell -type specific, as two additional cell lines demonstrated
increases in FHIT expression after being deprived of growth factors.
FHIT expression during growth factor depletion is dependent on PIP3 kinase
dependent phosphorylation of AKT.

The AKT/PIP3K complex functions downstream of many growth factor
receptor families as second messenger kinases involved in transmitting pro-growth/
proliferation signals to the nucleus from growth factor receptors imbedded in the cell
membrane (Manning,B.D. and Cantley,L.C. 2007). To follow the mitogen responsive
pathway downstream, PIP3K was examined to determine if repression of this kinase
could alter FHIT expression.
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Figure 43. HCT116 colon carcinoma cells demonstrate an increase in FHIT protein
levels after being deprived of mitogens.
HCT116 cells expressing wtp53 were treated with and without 10% FBS for 48 hours.
FHIT protein levels for each treatment condition were assessed by Western blot to reveal
an increase in FHIT protein in cells deprived of serum compared to those in complete
media.

140

141

Figure 44 . FHIT expression levels increase in response to mitogen removal from
MCF10A immortalized epithelial cells.
MCF10A cells were treated with and without EGF present in culture media for 96 hours.
FHIT protein (left) and mRNA levels (right) were assessed by Western blot and RT-PCR,
respectively. FHIT expression is shown to increase compared to levels in cells grown
with EGF present in culture media.
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Figure 45. The AKT / PIP3K pathway
AKT is phosphorylated by active PIP3K after growth factor receptor stimulation. Acting
as a second messenger, AKT transduces pro-growth signals by phosphorylating and either
activating or suppressing oncogenic or tumor suppressive factors, respectively.
Adapted from: Cell Signaling Technologies, Product Pathways,
http://www.cellsignal.com/reference/pathway/pdfs/Akt_PKB.pdf
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MCF7 cells were treated with the PIP3 kinase inhibitors wortmannin and
caffeine each for 12 hours (Foukas,L.C., Daniele,N., et al. 2002, Hashimoto,T., He,Z., et
al. 2004, Kong,D. and Yamori,T. 2008). An increase in FHIT mRNA expression was
observed 12 hours after treatment with both PIP3 kinase inhibitors (data not shown).
Treatments with wortmannin (Figure 46) and an additional specific PIP3K inhibitor—LY294002 (Figure 47), were also performed by treating MCF7 cells with each drug for
increasing amounts of time. Cells were treated for a range of times (between 0 to 50
hours) and resulted in time-dependent increases in FHIT mRNA expression under each
treatment condition. For each treatment condition, the amount of AKT phosphorylation
was used to determine the degree of inhibition of PIP3K kinase activity by Western blots
(Figure 46 and 47, bottom panels). Also, cells treated with LY-294002 were examined for
p27 and Gadd45a expression. Both of these genes are normally elevated in response to
PI3K inhibition (Greenburg et al, 2002).
Suppression of FHIT gene expression is dependent on AKT.

To verify that phosphorylation of AKT, a direct target of PI3 kinase activity,
also decreased after serum deprivation, serum starved MCF7 cells were probed for AKT
protein levels and compared to those from cells grown in 10% FBS (Figure 48). As
anticipated, total AKT protein stability was significantly reduced after removing growth
factors and arresting cells for 48h (Figure 48, right panel). Therefore it was possible that
AKT could be regulating FHIT gene expression. To further explore this mechanism of
regulation, exogenous constitutively active AKT (ca-AKT) or kinase-dead AKT (KDAKT) were transfected into MCF7 cells which were subsequently serum
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Figure 46. Inhibition of PIP3 kinase activity with wortmannin leads to upregulation
FHIT gene expression.
MCF7 cells were treated with 1µM wortmannin, a specific inhibitor of PIP3 kinase
activity for increasing amounts of time and then analyzed for FHIT mRNA expression.
FHIT mRNA expression increases when normalized to the level of FHIT mRNA from the
DMSO vehicle control (top panel). AKT phosphorylation by PIP3K was used to
determine the efficiency of PIP3K inhibition by wortmannin treatment. A decrease in
phosphorylation of AKT is noted in cells exposed to wortmannin for increasing amounts
of time compared to DMSO control and mock treated cells (bottom panel).
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Figure 47. Inhibition of PIP3 kinase with LY-294002 leads to an upregulation FHIT
gene expression.
MCF7 cells were treated with 50µM LY-294002, a specific PIP3K inhibitor for increasing
amounts of time and then analyzed for FHIT, p27 (top panel) and Gadd45a mRNA
expression (center panel). AKT phosphorylation by PIP3K was used to determine the
efficiency of inhibitor treatment (bottom panel).
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Figure 48. AKT protein stability decreases in MCF7 cells after mitogen removal.
To determine the effect of mitogen removal on AKT expression, MCF7 cells were
treated with serum free media for 48h. Following treatment, protein extracts were
assessed for AKT and FHIT protein expression by Western blot.
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Figure 49 . Constitutively active AKT partially impedes the serum deprivationdependent increase in FHIT expression normally seen after growth factor
deprivation.
In order to assess modulation of FHIT expression by AKT, MCF7 cells were
transfected with expression plasmids encoding no protein (CMV), constitutively
active AKT (CA-AKT) or kinase dead AKT (KD-AKT) prior to being serum deprived
or remaining in complete media. Cells were deprived of all growth factors for 72h
and assayed for FHIT transcript levels by RT-PCR.
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starved for 72h. Analysis of FHIT mRNA levels by qPCR revealed that ca-AKT was able
to partially 13 block—likely due to partial efficiency of transient transfection, the increase
in FHIT mRNA normally seen in response to serum deprivation while the kinase dead
mutant showed no inhibition of FHIT upregulation (Figure 49). The results from both of
these experiments provided support that FHIT is regulated by the PIP3K/AKT pathway
downstream of growth factor receptor activity.
Determination of trans-acting factor(s) responsible for mitogen depletion-dependent
transactivation of FHIT downstream of PIP3K and AKT.
Applying what is known regarding transcription factors regulated by AKT, the
factors most likely to regulate tumor suppressive genes such as FHIT were selected for
further analysis. The Forkhead transcription factors or FOXO’s are a family of genes that
have roles in aging, tumor suppression, cell cycle arrest and apoptosis (Arden,K.C. 2008,
Dansen,T.B. and Burgering,B.M. 2008, Maiese,K., Chong,Z.Z., et al. 2009, Weidinger,C.,
Krause,K., et al. 2008). They are homologues of the Daf-16 gene in C. elegans which is
involved in aging and insulin signaling pathways (Huang,H. and Tindall,D.J. 2007).
FOXO transcription factors are negatively regulated downstream of AKT by
phosphorylation resulting in sequestration from the nucleus when the cell is actively
involved in growth and cell division (Huang,H. and Tindall,D.J. 2007). With the onset of
growth arrest, such as during the absence of mitogenic stimulus, AKT is no longer active.
FOXOs are thus no longer phosphorylated and are therefore able to enter into the nucleus
13

The efficiency of transient transfections are typically less than 100% which results in only a partial response to
treatment when using total RNA in qPCR analysis.
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and transactivate stress-responsive target gene targets. Notable FOXO target genes
include KLF4, p27, p21, GADD45, BIM, FasL, and PUMA (Tran,H., Brunet,A., et al.
2002, You,H., Pellegrini,M., et al. 2006, Yusuf,I., Kharas,M.G., et al. 2008, Zhu,S.,
Evans,S., et al. 2008). These genes have roles in tumor suppression either through cell
cycle regulation through inhibition of cyclin dependent kinases (p27 and p21) and
apoptosis (BIM and FasL) or are involved in DNA repair as is the case with
GADD45(Huang,H. and Tindall,D.J. 2007). Whether the FOXOs preferentially bind to
and activate gene expression of apoptotic or cell cycle arrest and DNA repair genes is
believed to be determined by the degree of FOXO acetylation which is controlled by the
SIRT family of deacetylases (Giannakou,M.E. and Partridge,L. 2004, Huang,H. and
Tindall,D.J. 2007, Wang,F., Nguyen,M., et al. 2007).
Further support for FOXO regulation of FHIT stems from the observation
that FHIT expression may modulate during the cell cycle. FOXO protein stability
increases downstream of the E3 ligase Skp2 during G1-S, so it is possible that FOXO
could be contributing to the regulation of FHIT’s oscillatory behavior during the cell
cycle (see Figure 39 and 40) (Dehan,E. and Pagano,M. 2005, Huang,H., Regan,K.M., et
al. 2005). Lastly, considering FHIT’s role in tumor suppression through cell cycle arrest
and apoptosis (see FHIT background section), the FOXO transcription factors are ideal
candidates for regulation of FHIT transcription downstream of the growth factor
receptor/AKT/ PIP3 kinase pathway due to their tumor suppressive characteristics.
To begin to examine if FOXO could be regulating the transcription of FHIT,
the genomic DNA sequences up and downstream of the FHIT transcription start site were
computationally searched for FOXO consensus binding sequences. Two were located at
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the beginning of the 1st intron (Figure 50). Of these two potential binding sites, the
sequence corresponding to the site furthest upstream was 100% conserved in both the
mouse and human FHIT introns (Figure 51).
Overexpression of the human FOXO transcription factor family leads to upregulation in
FHIT mRNA and protein expression.
To explore the possibility that FOXO transcription factors may be involved in
FHIT regulation—FOXO1 TM, FOXO3a, FOXO3a TM 14, and FOXO4 were each
overexpressed in MCF7 cells. Exogenous expression of all four FOXO family members
led to an increase in both FHIT mRNA and protein levels in cells analyzed 48h posttransfection (Figure 52, FHIT mRNA and Figure 53, FHIT protein). It was also of
interest to determine if this increase in FHIT expression could be seen in a p53 –null cell
line. This needed to be addressed based on earlier observations where FHIT increased in
expression after siRNA targeting Hdm2/X in MCF7 cells. Therefore, the same FOXO
overexpression experiments were repeated in SAOS-2 osteosarcoma cells followed by
Western blotting for FHIT protein expression. Although FHIT mRNA levels in these
cells are lower than levels in breast and colon cells (RT-PCR data not shown), a
detectable increase in FHIT protein is still evident in SAOS-2 cells overexpressing
human FOXO family members compared to CMV transfected SAOS-2 cells (Figure 54).

14

The FOXOs denoted with TM (triple mutant) contain mutations in three
serines that when phosphorylated by AKT, trigger nuclear export and therefore inhibit
transactivation of FOXO target genes.
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Figure 50. Potential FOXO3a transcription factor binding sites within the FHIT
promoter.
Two FOXO binding sites were located in the first intron of the FHIT gene— 387 and 544
bps downstream of the FHIT transcription start site, respectively. Both sites had >85%
similarity to the core FOXO3a consensus binding site.
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Figure 51. FOXO3a consensus site 2 is conserved in mouse and human FHIT
intron 1.
Using the University of California Santa Cruz Genome Browser to assess the degree of
sequence homology between mammalian species, it was determined that FOXO3a core
consensus sequence #2 maintains 100% conservation between mouse and human.
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FOXO-dependent upregulation of FHIT gene expression requires nuclear localization
of FOXO.
To investigate whether modulation of FHIT expression in response to FOXO
overexpression requires FOXO to actually enter the nucleus, an estrogen receptor (ER) –
FOXO3a fusion construct was expressed in MCF7 cells. Nuclear import of the ERFOXO3a fusion protein can then be triggered after the addition of the partial estrogen
agonist tamoxifen (4-OHT) (M. Greenberg., et al. 2002). When ER binds to tamoxifen,
translocation of activated ER into the nucleus occurs. This particular estrogen receptor
also contains mutations that make it resistant to the effects of endogenous estrogens so
only tamoxifen can trigger nuclear localization. This fusion construct will probe the
dependence of FOXO directly transactivating FHIT based on the amount of time required
to see increases in FHIT transcription after 4-OHT addition and determine if FOXO must
also be in the nucleus for FHIT upregulation to occur.
MCF7 cells were infected with lentiviral FOXO3a TM-ER fusion expression
construct described above. Forty-eight hours after infection cells were treated with 1µM
4-OHT for increasing amounts of time and analyzed by RT-PCR to measure changes in
FHIT mRNA and Gadd45a mRNA (Figure 55). As expected, both genes increased to the
same degree after 4-OHT treatment. Because FHIT mRNA levels modulate similarly to
GADD45a—a known target of FOXO3a, this data provides further support that FHIT is a
target of FOXO3a. This experiment was repeated; with the exception that FHIT
expression was analyzed after only two hours of 1 μM 4-OHT treatment and resulted in
an increase in both FHIT and GADD45 mRNA (Figure 56). Also as an additional
negative control, lenti-ER empty vector was induced in cells under the same conditions as
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lenti-FOXO3aTM-ER infected cells but failed to demonstrate any increase in FHIT or
Gadd45a mRNA levels after two hours of 0.5μM 4-OHT treatment. Because FHIT
mRNA levels modulate similarly to GADD45a—a known target of FOXO3a, this data
provides further support that FHIT is a direct target of FOXO3a.
Regulation of FHIT gene expression downstream of PIP3K is dependent on endogenous
FOXO3a.

To determine if upregulation of FHIT gene expression after chemical
inhibition of PIP3K was dependent on FOXO transcription factors, MCF7 cells were
infected and selected shRNA expression targeting either FOXO3a or FOXO1 and
subsequently treated with wortmannin for 24h. Although FHIT expression still increased
downstream of PIP3K inhibition when FOXO1 expression was knocked down, no
increase in either FHIT transcript (Figure 57) or protein levels (Figure 58) was apparent
in cells that were stably expressing shRNA targeting FOXO3a. This result, coupled with
those seen after tamoxifen-inducible FOXO3a-ER nuclear localization, provide evidence
that expression of the FHIT tumor suppressor gene is upregulated by the FOXO3a tumor
suppressor after its release from oncogenic PIP3K/AKT signaling and cytoplasmic
sequestration as cells enter a quiescent state in the absence of growth factor stimulation.
Proposed mechanisms of cell cycle and HdmX and 2-mediated regulation of FHIT gene
expression

To address other modes of FHIT gene expression modulation in addition to
that occurring as cells enter quiescence, it is noteworthy that FOXO transcription factors
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are not only active during G1 arrest (Dansen,T.B. and Burgering,B.M. 2008, Huang,H.
and Tindall,D.J. 2007) but their stability is also regulated in a cell cycle dependent
manner by the E3 ligase Skp2 (Nakayama,K.I., Hatakeyama,S., et al. 2001). This protein
ubiquitinates FOXO as cells transition from G1 into S phase and effectively targets it to
the proteosome (Dehan,E. and Pagano,M. 2005, Huang,H., Regan,K.M., et al. 2005).
Thus as cells proceed through S phase it would be expected that the expression levels of
FOXO transcriptional target genes would also decrease. This could explain why FHIT
levels drop after entry into S phase begins to increase again after completion of G2/M
and reentry into G1.
Additionally, FOXO transcription factors are negatively regulated by Hdm2 and
HdmX. Hdm2 has been shown to act as an E3 ligase for all three mammalian FOXO
transcription factors—targeting each to the proteosome for degradation (Brenkman,A.B.,
de Keizer,P.L., et al. 2008, Fu,W., Ma,Q., et al. 2009). Further, HdmX has been shown to
be stabilized after being phosphorylated at S367 by activated AKT. This phosphorylation
triggers C-terminal binding of the small scaffold protein 14-3-3. Furthermore, it is known
that HdmX can facilitate stabilization of Hdm2 (Lopez-Pajares,V., Kim,M.M., et al.
2008). Moreover, Hdm2 is itself stabilized by AKT (Lopez-Pajares,V., Kim,M.M., et al.
2008) as well as imported into the nucleus to ubiquitinate nuclear localized transcription
factors such as p53 (Mayo,L.D. and Donner,D.B. 2001) and thus presumably FOXOs as
well. These AKT-dependent mechanisms of Hdm2 activation would be expected to
promote the ubiquitination and proteosomal targeting FOXO transcription factors by
Hdm2. It is anticipated that siRNA-mediated Hdm2 mRNA degradation and protein
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Figure 52. FHIT mRNA expression increases in response to exogenous expression of
the FOXO transcription factors 1, 3a and 4.
MCF7 cells were transfected with either CMV empty vector, FLAG -FOXO1 TM (triple
mutant), FLAG-FLAG-FOXO3a, FLAG-FOXO3a TM or FLAG-FOXO4. Forty eight
hours after transfection, cells were analyzed by RT-PCR to determine levels of FHIT
mRNA in each treatment condition.
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Figure 53. FHIT protein expression increases in response exogenous expression of
the FOXO transcription factors 1, 3a and 4.
MCF7 cells were transfected with either CMV empty vector, FLAG -FOXO1 TM ,
FLAG-FLAG-FOXO3a, FLAG-FOXO3a TM or FLAG-FOXO4. Forty eight hours after
transfection, cells were lysed and 50µg of total protein from each transfection was
analyzed by SDS-PAGE and probed with indicated antibodies.
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Figure 54. FHIT protein expression increases in response to exogenous expression of
the FOXO transcription factor family is p53 independent.
p53-null SAOS-2 osteosarcoma cells were transiently transfected with either CMV empty
vector, FLAG -FOXO1 TM , FLAG-FLAG-FOXO3a, FLAG-FOXO3a TM or FLAGFOXO4. Forty eight hours after transfection, cells were lysed and 50µg of total protein
from each transfection was analyzed by SDS-PAGE and probed with indicated
antibodies. It is important to note that the FLAG antibody/ CMV lane contains a nonspecific band around the same size as FOXO1 and 3a.
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Figure 55. Nuclear localization of FOXO3a leads to an increase in FHIT transcript
levels.
A FOXO3a TM-estrogen receptor fusion construct was cloned and expressed in MCF7
cells by lentiviral infection. This fusion protein remains sequestered in the cytoplasm
until tamoxifen (4OHT) is added to growth media (top panel). Tamoxifen treatment
allows FOXO3a-ER to enter the nucleus where it can affect the transcription of FOXO
target genes. Center panel: Expression of the Foxo3a-ER protein is detected by anti-rat
HA antibody from H1299 protein extracts after infection, 7 days of Zeocin selection and
subsequent analysis by Western blot in only 25% of clones screened due to FOXOassociated cellular toxicity. Bottom Panel: FOXO3a-ER infection of MCF7 cells
followed by 4-OHT treatment 72h post-infection and RT-PCR analysis of FHIT and
Gadd45a mRNA at the indicated time points after 4-OHT expression demonstrate FHIT
levels increase in a comparable manner to Gadd45a—a known FOXO3a transcriptional
target after 4-OHT treatment.
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Figure 56. Nuclear import of FOXO3a results in FHIT and Gadd45a
upregulation after two hours of 4-OHT treatment.
Forty-eight hours after infection with either FOXO3a-ER or Control-ER virus each at a
MOI of 3, cells were treated with 1µM 4-OHT for two hours. An elevation of FHIT and
Gadd45a mRNA levels was evident in treated FOXO3a-ER expressing cells after
FOXO3a-ER entry into the nucleus.
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Figure 57. PIP3K-dependent suppression of FHIT transcription requires FOXO3a.
MCF7 cells were infected with lenti-shRNA expression constructs targeting either
FOXO1 or FOXO3a. After treatment with 3µM wortmannin, RNA was extracted and
analyzed for FHIT gene expression by RT-PCR. Knockdown of FOXO1 had no effect on
the increase of FHIT levels downstream of PIP3K inhibition. However, attenuation of
FOXO3a was able to completely block the increase in FHIT gene expression normally
seen after wortmannin-dependent inhibition of PIP3K. It is worth noting that endogenous
expression of FOXO3a versus FOXO1 is significantly higher in this cell line(>20 fold by
RT-PCR analysis, data not shown). This may explain why shRNA targeting FOXO3a
results in such a dramatic effect compared to that of shFOXO1 on FHIT expression, even
though overexpression of both FOXOs separately could drive FHIT expression.
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Figure 58. FHIT protein expression elevation after PIP3K inhibition is dependent on
FOXO3a.
MCF7 cells were infected with lenti-shRNA expression constructs targeting either
FOXO1 or FOXO3a. After selection, cells were treated with 3µM wortmannin for 24h.
Following this treatment FHIT protein levels were analyzed by Western blot.
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Figure 59. Proposed mechanism of regulation of FHIT gene expression by the AKT
/PIP3K/ FOXO3a pathway.
In dividing cells being stimulated with growth factor signals, PIP3K and AKT are
actively transducing pro-growth signals. AKT suppresses FOXO3a transactivation by
phosphorylation of three key serine residues to keep it out of the nucleus. In the event
that the cell enters quiescence as a result of growth factor deprivation, FOXO3a can enter
the nucleus and regulate transcription of grow suppressive target genes—one of which
being FHIT.
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destabilization as a result of siRNA mediated HdmX transcript reduction could also
release FOXO factors from ubiquitination by Hdm2. Thus, the increase in FHIT
transcript levels seen in mircroarray experiments involving siRNA mediated knockdown
of Hdm2 and HdmX may be explained through this mechanism.
DISCUSSION
In summary, this project began with investigating the regulation of two genes
derived from a microarray screen to search for new p53 targets. YPEL3 and FHIT gene
expression were both shown to be upregulated downstream of p53 protein stabilization in
a microarray screen that explored global gene expression modulation after RNAimediated reduction of p53’s negative regulators, Hdm2 and HdmX. Validation of
YPEL3 as a novel p53 target gene was very straightforward. All assays employed in
characterizing YPEL3 revealed that it behaved exactly as a classic p53 transcriptional
target. The first section of this dissertation provided significant experimental evidence to
validate this observation. Genotoxic stress induced by treatment with DNA-damaging
agents resulted in physiologic stabilization of p53 along with elevation of YPEL3
transcript and protein levels. Moreover, a cis-acting p53 response element within the
YPEL3 promoter was identified and shown to be bound by p53 protein in response to
genotoxic stress. Finally, data was presented demonstrating that YPEL3 elicited growth
inhibition of colony formation when expressed in tumor cells by causing these cells to
senesce. Similar growth suppressive phenotypes are typical of many other known p53
target genes. However, most of these genes are associated with the regulation of transient
inhibition of cell division or the induction of apoptosis. YPEL3 is unique in its ability to
trigger premature cellular senescence, and it stands out among many other p53 targets
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because it is among the first to play a role in this process.
To better understand YPEL3’s biological function and determine the mechanism of
how YPEL3 induces cellular senescence, the second portion of this dissertation detailed
the generation of a three-dimensional model of YPEL3’s protein structure. It was
hypothesized that predicting YPEL3’s protein structure may also aid in understanding the
biological events involved in the induction and maintenance of premature senescence.
Identifying structural homology between a predicted model of YPEL3 and other known
structures may provide new insights into this process. By using both the Rosetta ab initio
and I-TASSER structural prediction algorithms, a likely three-dimensional structure of
the YPEL3 protein was predicted which has significant structural homology to a family
of Methionine oxidoreductases. These enzymes catalyze redox-mediated antioxidant
reactions which dissipate intracellular reactive oxygen species (ROS) through the repair
of proteins damaged by ROS-mediated methionine to methionine sulfoxide oxidation.
Based on this similarity, YPEL3 may play a role in the cell’s response to oxidative stress.
Additionally, YPEL3 may normally function in the cell to quench reactive oxygen species
(ROS) by reversing oxidized methionine sulfoxide back to its reduced state.
Furthermore, as a p53 target, YPEL3 expression would be expected to be elevated in
response to oxidative stress. In the event that oxidative stress is severe, ROS-responsive
proteins (i.e. YPEL3) may become overwhelmed and reach a saturation point. As a
result, these enzymes may not have the required reducing conditions necessary to
regenerate back into an enzymatically functional state. This could contribute to perhaps
either conformational changes in protein structure or increased stability under prolonged
oxidizing conditions to act as a signal to trigger premature senescence. Thus, further
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investigation is necessary to assess potential roles YPEL3 may play in cellular
senescence, oxidative stress and aging, collectively.
In the third part of this dissertation, FHIT, a tumor suppressor gene often deleted
in epithelial-derived tumors, was also initially postulated to be regulated by p53. FHIT,
however was determined not to be a p53 target but rather a transcriptional target of
FOXO3a—another tumor suppressive transcription factor (Figure 59). Coincidentally,
FOXO3a gene expression is induced under similar conditions as p53 such as cell cycle
arrest, and certain types of genotoxic stress. In support of this, FHIT transcript levels are
elevated in response to the removal of mitogen-containing serum from breast, colon
carcinoma, and immortalized mammary epithelial cells. It has been demonstrated that
expression of FHIT is suppressed by the AKT/PI3K pathway in cells stimulated by
growth factor signaling. These proto-oncogenic kinases phosphorylate and, thereby
prevent FOXO3a from entering the nucleus. Thus, FOXO3a is only able to enter the
nucleus in the absence of mitogenic stimulation. In other words, induction of FHIT gene
expression is dependent on decreased PIP3K kinase activity and subsequent reduced AKT
phosphorylation which occurs in the absence of growth factor stimulation. As such,
quiescence-dependent elevation of FHIT mRNA can be elicited independently of mitogen
removal, by treatment with PI3K inhibitors, or attenuated by ectopic expression of
constitutively active AKT during serum deprivation. Further, ectopic expression of
FOXO transcription factors results in the upregulation of FHIT mRNA and protein levels.
FOXO must enter the nucleus for this modulation to occur. This is thought to be
necessary based on the fact that FHIT mRNA levels do not modulate in the presence of
cytoplasmic FOXO3a-estrogen receptor until 4-OHT treatment induces the fusion protein
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to enter the nucleus. Finally, experiments using shRNA targeting FOXO3a have revealed
that the modulation of FHIT gene expression is dependent on endogenous FOXO3a
expression levels.
This work provides vital insight into the molecular regulation of cell growth and
proliferation by expanding our understanding of the transcriptional regulation of two
important tumor suppressor genes. This information has clinical applicability in that it
has led to the identification of a new means to inhibit the growth of tumor cells— through
which the expression YPEL3 can force these cells to senesce. Also exciting is the fact
that YPEL3 has been shown to be downregulated in human tumors and may thus be a
potential tumor marker.
With respect to the FHIT tumor suppressor gene, there are currently more than 700
publications investigating its role in cancer. However, very little is known about how this
gene’s expression is regulated. It is now known that FHIT expression is normally kept
low in dividing cells by activated PIP3K and AKT. These oncogenic kinases indirectly
suppress FHIT’s transcription by preventing FOXO3a from entering the nucleus. It is
hoped that this work will be beneficial by enhancing our basic understanding of tumor
suppressor biology.
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